UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
X ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the fiscal year ended June 30, 2009
_____________________
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from________to_________
Commission file number 0-6658
____________________
SCIENTIFIC INDUSTRIES, INC.
_________________________________________
(Exact Name of Registrant in Its Charter)
Delaware 04-2217279
_______________________________ ___________________
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification No.)
70 Orville Drive, Bohemia, New York 11716
________________________________________ ____________________
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (631) 567-4700
__________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Name of each exchange on which registered
None None
___________________ _________________________________________
Securities registered pursuant to Section 12(g) of the Exchange Act:
Common Stock, par value $.05 per share
______________________________________
(Title of Class)
Indicate by check mark if the registrant is a well-known seasoned
issuer, as defined in Rule 405 of the Securities Act.
Yes [ ] No [ x ]
Indicate by check mark if the registrant is not required to file
reports pursuant to Section 13 or Section 15(d) of the Act.
Yes [ ] No [ x ]
Indicate by check mark whether the registrant(1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [ x ] No [ ]
Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Website, if any, every
Interactive Data File required to be submitted and posted pursuant
to Rule 405 of Regulation S-T (Section 232.405 of this chapter)
during the preceding 12 months (or for such shorter period that
the registrant was required to submit and post such files).
Yes [ ] No [ x ]
Indicate by check mark if disclosure of delinquent filers
pursuant to Item 405 of Regulation S-K (Section 229.405 of this
chapter) is not contained herein, and will not be contained,
to the best of registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of
this Form 10-K or any amendment to this Form 10-K. [ x ]
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer,
or a smaller reporting company. See the definitions of "large
accelerated filer," "accelerated filer " and "smaller reporting
company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer [ ] Accelerated filer [ ]
Non-accelerated filer [ ] Smaller reporting company [ x ]
(Do not check if a smaller reporting company)
Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Act) Yes [ ] No [ x ]
The aggregate market value of the voting stock held by
non-affiliates computed by reference to the average bid and asked
prices of such stock, as of August 28, 2009 is $1,540,200.
The number of shares outstanding of the registrant's common
stock, par value $.05 per share ("Common Stock") as of August
28, 2009 is 1,196,577 shares.
DOCUMENTS INCORPORATED BY REFERENCE
None.
Forward Looking Statements. The Company and its
representatives may from time to time make written or oral
forward-looking statements with respect to the Company's annual
or long-term goals, including statements contained in its filings
with the Securities and Exchange Commission and in its reports to
stockholders.
The words or phrases "will likely result," "are expected
to," "will continue to," "is anticipated," "estimate," "project"
or similar expressions identify "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995.
Such statements are subject to certain risks and uncertainties that
could cause actual results to differ materially from historical
earnings and those presently anticipated or projected. Readers are
cautioned not to place undue reliance on any such forward-looking
statements, which speak only as of the date made.
PART I
Item 1. Business.
General. Incorporated in 1954, Scientific Industries, Inc.,
a Delaware corporation (which along with its subsidiaries, the
"Company"), is engaged in the design, manufacture, and marketing of
standard benchtop laboratory equipment ("Benchtop Laboratory
Equipment") and since November 2006, upon the acquisition of the
outstanding shares of Altamira Instruments, Inc., a Delaware
corporation ("Altamira") customized catalyst research instruments
("Catalyst Research Instruments"). The Company's products are used
primarily for research purposes by universities, hospitals,
pharmaceutical companies, clinics, medical device manufacturers,
petrochemical companies and other related industries.
Operating Segments. The Company views its operations as two
segments: the manufacture and marketing of standard benchtop
laboratory equipment for research in university, hospital and
industrial laboratories sold primarily through laboratory equipment
distributors (Benchtop Laboratory Equipment Operations), and the
manufacture and marketing of custom-made catalyst research
instruments for universities, government laboratories, and chemical
and petrochemical companies (Catalyst Research Instruments
Operations). For certain financial information regarding the
Company's operating segments, see Note 3 to the consolidated
financial statements included under Item 8.
Products.
Benchtop Laboratory Equipment. The Company's Benchtop
Laboratory Equipment products consist of mixers and disruptors,
rotators/rockers, refrigerated incubators and magnetic stirrers.
The Vortex-Genie(R) 2 Mixer is the Company's principal product;
sales of this product (excluding accessories) represented
approximately 44% and 39% of the Company's total sales for the
fiscal years ended June 30, 2009 ("fiscal 2009") and June 30, 2008
("fiscal 2008"), respectively, or 69% and 70%, respectively, of the
segment's sales for fiscal 2009 and fiscal 2008.
The vortex mixer is used to mix the contents of test tubes,
beakers, and other various containers by placing such containers on
a rotating cup or other attachments which cause the contents to be
mixed at varying speeds.
The Company's additional mixers and disruptors include the
Vortex-Genie 1, a high speed touch mixer; the Vortex-Genie 2T, a
mixer with an integral timer; the Disruptor Genie(R), a patented cell
disruptor; the MicroPlate Genie(R) and Multi-MicroPlate Genie(R)
mixers, specialty mixers designed to mix and vortex the contents
of microplates; the Digital Vortex-Genie 2, a vortex mixer
incorporating digital control and display; and introduced in
July 2008, the Multi Vortex-Genie, a large capacity multi-vessel
vortex mixer.
The Company's Roto-Shake Genie(R), a patented benchtop
multi-purpose rotator/rocker was designed by the Company to
rotate and rock a wide variety of containers which are
magnetically attached to the unit's magnetized platform. The
Enviro-Genie(R) Refrigerated Incubator and Incubator-Genie(TM) are
multi-functional benchtop environmental chambers designed to
perform various shaking and stirring functions under controlled
environmental conditions.
The Benchtop Laboratory Equipment products also include
a complete line of magnetic stirrers including the MagStir Genie(R),
a patented high/low programmable magnetic stirrer; the MultiMagStir
Genie(R), a four-place high/low programmable magnetic stirrer; the
MegaMag Genie(TM), a large volume magnetic stirrer available in
analog and digital versions; and the QuadMag Genie(TM) magnetic
stirrer, a four-place powerful general purpose stirrer.
Catalyst Research Instruments. The Catalyst Research
Instrument products are offered through the Company's subsidiary,
Altamira. Its flagship product is the AMI-200(TM), which is used
to perform traditional catalyst characterization experiments on an
unattended basis. The product also features a stand-alone personal
computer to control the instrument and incorporates proprietary
LabVIEW(R) -based software. In June 2009, the Company introduced the
AMI-300(TM) Catalyst Characterization Instrument which incorporates
a sophisticated data handling package and is designed to perform
dynamic temperature-programmed catalyst characterization experiments.
All AMI model instruments are customized to a customer's individual
requirements.
Other Catalyst Research Instrument products include reactor
systems, high throughput systems and micro-activity reactors. The
Company's BenchCAT(TM) custom reactor systems are available with
single and multiple reactor paths and with reactor temperatures up
to 1200 degrees celsius. The systems feature multiple gas flows,
are available in gas and gas/liquid configurations, and also feature
one or more stand-alone personal computers with the LabVIEW(R)-based
control software.
Two other Catalyst Research Instrument products are the
Celero(TM) and the PID MA-Reference Reactor, sales of which to date
have been insignificant. The Celero(TM), offered under a license
from Symyx Corporation, is a high throughput system, designed to
provide high throughput screening in multiples of 8 channels and is
typically used to screen multiple catalysts, under the same
conditions of temperature, pressure, and gas/liquid flows.
The PID MA-Reference Reactor is offered pursuant to an
exclusive distribution agreement covering North America with PID
Eng. & Tech in Spain. It is a highly-automated, micro-activity
reactor featuring sophisticated microprocessor control with touch-
screen and TCP/IP Ethernet communications used for catalyst activity,
selectivity, optimization and kinetics studies.
Product Development. The Company designs and develops
substantially all of its products. Company personnel formulate
plans and concepts for new products and improvements or
modifications of existing products. The Company engages outside
consultants to augment its capabilities in areas such as industrial
and electronics design.
In general, due to the reliance on sales through the catalog
distribution system, it takes two to three years for a new benchtop
laboratory equipment product to begin generating meaningful sales.
Major Customer. Sales principally of the Vortex-Genie 2
Mixer, to one customer, which is one of the two major distributors
of laboratory equipment, represented approximately 9.8% and 11.3%
of total sales for fiscal 2009 and fiscal 2008, respectively.
Sales of Catalyst Research Instrument products are generally
pursuant to a few large orders amounting on average to over
$100,000 to different customers with no single customer
accounting for more than 10% of the Company's net sales for
fiscal 2009 or 2008.
Marketing.
Benchtop Laboratory Equipment. The Company's Benchtop
Laboratory Equipment products are generally distributed and
marketed through an established network of domestic and
overseas laboratory equipment distributors, who sell the Company's
products through printed catalogs, websites and sales force.
See "Major Customer". The Company also markets products through
attendance at industry trade shows, trade publication advertising,
brochures and catalogs, the Company's website, and commencing,
in June 2009, through the efforts of its first sales manager.
Catalyst Research Instruments. The Company's Catalyst
Research Instruments are sold directly worldwide to universities,
government laboratories, and chemical and petrochemical companies
through its sales personnel and independent representatives
engaged on a commission basis. Its marketing efforts include
attendance at various trade shows, Altamira's website, outside
sales representatives, and printed materials.
Assembly and Production. The Company has an operating
facility in Bohemia, New York from which its Benchtop Laboratory
Equipment Operations are conducted and another in Pittsburgh,
Pennsylvania from which its Catalyst Research Instruments Operations
are conducted. The Company's production operations principally
involve assembly of components supplied by various domestic and
international independent suppliers. In both fiscal 2009 and 2008
a substantial portion of benchtop laboratory equipment components
were produced overseas, with purchases through a U.S. vendor
accounting for approximately 11% and 24% for fiscal 2009 and fiscal
2008, respectively, of the Company's total material purchases.
See "Risk Factors - The Company is Heavily Dependent on Outside S
uppliers for the Components of Its Products".
Patents, Trademarks, Licenses and Franchises.
Patents. The Company holds several United States patents
relating to its products, including a patent which expires in
September 2015 for the TurboMix(TM), an accessory to the Vortex-Genie
2 Mixer, a patent which expires in July 2016 on the Roto-Shake
Genie(R); and a patent which expires in November 2022 on the MagStir
Genie(R), MultiMagStir Genie(R), and Enviro-Genie(R).
Trademarks. The Company has various proprietary marks,
including AMI(TM),BenchCAT(TM), Celero(TM), Disruptor Beads(TM),
Disruptor Genie(R), Enviro-Genie(R), Genie(TM), MagStir Genie(R),
MegaMag Genie(TM), MicroPlate Genie(R), MultiMagStir Genie(R),
Multi-MicroPlate Genie(R), QuadMag Genie(TM), Roto-Shake Genie(R),
TurboMix(TM), and Vortex-Genie(R), each of which it considers
important to the success of the related product. The Company
also has several trademark applications pending. No representation
can be made that any application will be granted or as to the
protection that any existing or future trademark may provide.
Licenses. The Company has several licensing agreements
for technology and patents used in the Company's business. A
non-exclusive worldwide sublicense from Fluorometrix Corporation
relates to the development, production and marketing of a line of
bioreactor vessels, including culture bags with integral sensors
for pH and oxygen in volumes ranging from 250 milliliters to 5
liters for laboratory incubator systems. The Company also licenses
the technology related to its patent for the Roto-Shake Genie from a
local university, and licenses a patent related to its TurboMix
attachment for the Vortex-Genie and Disruptor Genie from an
independent inventor. Altamira has a license with respect to
technology related to the Celero line of products from Symyx
Corporation.
Foreign Sales. The Company's sales to overseas customers,
including distributors, principally in Asia and Europe, accounted
for approximately 45% and 51% of the Company's net sales for
fiscal 2009 and fiscal 2008, respectively. Such sales are paid in
United States dollars and are therefore not subject to risks of
currency fluctuation, foreign duties and customs.
Seasonality. The Company does not consider its business
to be seasonal.
Backlog. The backlog for Benchtop Laboratory Equipment
products is not significant because this line of products is
comprised of standard catalog items requiring lead times which
usually are not longer than two weeks. The backlog for Catalyst
Research Instrument products as of June 30, 2009 was $1,216,600,
most of which is expected to be filled by December 31, 2009.
Competition. Most of the Company's competitors are
substantially larger and have greater financial, production and
marketing resources than the Company. Competition is generally
based upon technical specifications, price, and product recognition
and acceptance. The Company's main competition for its Benchtop
Laboratory Equipment products in the United States derives from
private label brand mixers offered by the two largest laboratory
equipment distributors in the United States, who dominate the end
user market. The Company believes its Benchtop Laboratory Equipment
products and trademarks are factors in the vortex mixers market
around the world.
The Company's major competitors for its Benchtop Laboratory
Equipment are Henry Troemner, Inc. (private label supplier to the
two largest laboratory equipment distributors in the U.S. and Europe),
Barnstead/Thermolyne Corporation, (an Apogent Technologies company
owned by Thermo Fisher Scientific, Inc.), IKA-Werke GmbH & Co.
KG, a German company, and Heidolph Instruments GmbH, a German
company.
The primary competition for the Company's Catalyst
Research Instrument products is in the form of instruments produced
internally by research laboratory staffs of potential customers.
Other competitors in the United States include Quantachrome
Instruments, and Micromeritics Instrument Corporation, each a
privately-held company.
Research and Development. The Company incurred research
and development expenses, the majority of which relate to new
Benchtop Laboratory Equipment products, of $452,600 during fiscal
2009 compared to $394,600 during fiscal 2008. The Company
expects research and development expenditures for each of its
two operations in the fiscal year ending June 30, 2010 will not
materially increase from the fiscal 2009 amount.
Government and Environmental Regulation. The Company's
products and claims with respect thereto have not required
approval of the Food and Drug Administration or any other
government approval. The Company's manufacturing operations,
like those of the industry in general, are subject to numerous
existing and proposed, if adopted, federal, state, and local
regulations to protect the environment, to establish occupational
safety and health standards and to cover other matters. The
Company believes that its operations are in compliance with
existing laws and regulations and the cost to comply is not
significant to the Company.
Employees. As of August 28, 2009, the Company employed
26 persons (15 for the Benchtop Laboratory Equipment Operations
and 11 for the Catalyst Research Instruments Operations) of
whom 23 were full-time, including its three executive officers.
None of the Company's employees is represented by any union.
Available Information. The Company's Annual Report to
Stockholders for fiscal 2009, includes its Annual Report on
Form 10-K. The Annual Report will be mailed to security holders
together with the Company's proxy material and solicitation as
it relates to the Company's 2009 Annual Meeting of Stockholders.
All the Company's reports, including Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and
other information filed with, or furnished to, the Securities and
Exchange Commission (the "SEC" or the "Commission"), including
amendments to such reports, are available on the SEC's website
that contains such reports, proxy and information statements, and
other information regarding companies that file electronically
with the Commission. This information is available at www.sec.gov.
In addition, all the Company's public filings can be accessed
through the Company's website at
http://scientificindustries.com/financial.html.
Item 1A. Risk Factors.
In connection with the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995, important risk
factors are identified below that could affect the Company's
financial performance and could cause the Company's actual
results for future periods to differ materially from any opinions
or statements expressed with respect to such future periods in
any current statements. The Company undertakes no obligation
to publicly revise any forward-looking announcements to reflect
future events or circumstances.
Dependence on a Major Customer
The laboratory equipment industry is dominated in the U.S.
by two major laboratory equipment distributors, one of which, is
the Company's largest customer. Sales to this customer accounted
for approximately 9.8% and 11.3% of total sales (15% and 20% of
the sales of the Benchtop Laboratory Equipment Operations) for
fiscal 2009 and 2008, respectively. During fiscal 2009 this
distributor discontinued the inclusion of the Company's Benchtop
Laboratory Equipment products in its new catalog which was released
in January 2009 which was a major factor in the reduction in sales
to this distributor for fiscal 2009. While the Company's products
continue to be offered through the distributor's website, and
upon requests made directly to the distributor from customers, the
Company expects the continuation of reduced orders from this
distributor. To mitigate the adverse effect of the catalog
discontinuance, the Company has increased its advertisements
placed in the distributor's interim publications, hired a new
sales manager who is working with the distributor's sales
representatives, and is expanding its selling efforts directed to
other distributors. No representation can be made that the
Company will be successful in such efforts or as to the extent of
the adverse effect on the future operating results of the
Company.
One Benchtop Laboratory Equipment Product Accounts for a
Substantial Portion of Revenues
The Company has a limited number of Benchtop Laboratory
Equipment products with one product, the Vortex-Genie 2 Mixer,
accounting for approximately 69% and 70% of Benchtop Laboratory
Equipment sales, for fiscal 2009 and fiscal 2008, respectively,
and 44% and 39% of total sales for fiscal 2009 and fiscal 2008,
respectively.
The Company is A Small Participant in Each of the Two Industries
in Which It Operates
The Benchtop Laboratory Equipment industry is highly
competitive. Although the Vortex-Genie 2 Mixer has been widely
accepted, the annual sales of the Benchtop Laboratory Equipment
products ($3,848,400 for fiscal 2009 and $3,770,500 for fiscal 2008)
are significantly lower than the annual sales of many of its
competitors in the industry. The principal competitors are
substantially larger with much greater financial, production and
marketing resources than the Company. In the past few years, there
have been several entrants into the vortex mixer market, including
the manufacturer of the private label mixers of the two largest
distributors.
The production and sale of Catalyst Research Instruments
products is highly competitive. Altamira's competitors include
several companies with greater resources and many laboratories
which produce their own instruments.
The Company's Ability to Grow and Compete Effectively Is In
Part Dependent on Its Ability to Develop and Effectively Market
New Products
Over the past ten years, the Company has continuously
invested in the development and marketing of new Benchtop
Laboratory Equipment products with a view to increasing revenues
and reducing the Company's dependence on the Vortex-Genie 2 Mixer.
Gross revenues derived from new Benchtop Laboratory Equipment
products (those other than the Vortex-Genie 2 Mixer) amounted to
$1,217,300 and $1,145,200, respectively, for fiscal 2009 and
fiscal 2008. The segment's ability to compete will depend upon the
Company's success in developing and marketing new laboratory
equipment as to which no assurance can be given.
The Company relies primarily on distributors and their
catalogs to market its Benchtop Laboratory Equipment products.
Accordingly, sales of new products are heavily dependent on the
distributors' decision to include and retain a new product in the
distributors' catalogs and on their websites. It may be at least
24 to 36 months between the completion of development of a product
and the distribution of the catalog in which it is first offered.
In June, 2009 the Company hired a new sales manager with a view to
increasing sales through distributors and directly to end users.
No assurance can be given that the amounts allocated by
the Company for its new product development and sales and
marketing programs will be sufficient to develop additional
commercially feasible products or that distributors will include
or retain any particular product in their catalogs and websites.
In June 2006, the Company received a nonexclusive sublicense
from Fluorometrix Corporation to develop, produce and sell a line of
bioreactor vessels with integral sensors for pH and oxygen in volumes
of 250 milliliters up to 5 liters for laboratory systems. The
Company's efforts to develop products which incorporate the disposable
sensor technology commenced in fiscal 2009. No assurance can be
given that any commercially feasible product will be developed or that
material revenues, if any will result therefrom.
The Company's Catalyst Research Instruments line of products
consists of only a few products. The ability of the Company to
compete in this segment and expand the line will depend on its
ability to make engineering improvements to existing products and
develop and add new products incorporating more current technology.
During fiscal 2009, the Company towards this end, hired a new
software engineer and engaged outside product design services to
develop new catalyst research products, one of which was introduced
in June 2009. No assurance can be given that the Company's new
product development and related marketing efforts will enable the
segment to be competitive or that the Company will be successful
in developing or improving products which will be commercially
feasible.
The Company May Be Subject to General Economic, Political, and
Social Factors
Orders for the Company's products, particularly the
Catalyst Research Instruments products, depend in part, on the
customer's ability to secure funds to finance purchases.
Availability of funds can be affected by budgetary constraints.
Factors such as a general economic recession, as experienced
during fiscal 2009, or another major terrorist attack could have
a negative impact on the availability of funding including
grants to potential customers.
The Company's ability to secure new Catalyst Research
Instruments orders can also be affected by changes in domestic
and international policies pertaining to energy and the
environment.
The Company is Heavily Dependent on Outside Suppliers for the
Components of Its Products
During the last few years, the Company had relied on a
single supplier for certain components of its Benchtop
Laboratory Equipment products, including the Vortex-Genie 2.
Purchases from this supplier for several reasons, including
quality and pricing were reduced to approximately 11% for
fiscal 2009 of the Company's material purchases from 24% for
fiscal 2008, and to 16% of the segment's material purchases
for fiscal 2009 from 40% for fiscal 2008).
Many of the Company's suppliers, including United
States vendors, produce the components directly or indirectly
in overseas factories, and are subject to long lead times
and potential other risks related to production in a foreign
country. To minimize the risk of supply shortages, the
Company keeps more than normal quantities on hand of the
critical components that cannot easily and quickly be procured
or, where feasible and cost effective, purchases from more
than one supplier.
The Company's Ability to Compete Depends in Part on Its Ability
To Secure and Maintain Proprietary Rights to its Products
The Company does not have any patent protection for its
principal product the Vortex-Genie 2 Mixer and limited patent
protection on a few other Benchtop Laboratory Equipment
products. As a result, there are several competitive products
available in the marketplace possessing similar technical
specifications and design. The Company does not have any
patent protection for any of its Catalyst Research Instruments
products, except as a licensee to a line of Celero products,
sales of which have not been significant.
There can be no assurance that the Company will be
successful in obtaining additional patents, that any patent
issued or licensed to the Company provides or will provide
the Company with competitive advantages or will not be
challenged by third parties or that the patents of others
will not prevent the commercialization of products developed
by the Company. Furthermore, there can be no assurance
that others will not independently develop similar products
or design around the patents related to the Company's products.
Any of the foregoing activities could have a material adverse
effect on the Company. Moreover, the enforcement by the
Company of its patent rights may require substantial
litigation costs.
The Company Has Limited Management Resources
The loss of the services of any of Ms. Helena Santos,
the Company's Chief Executive and Financial Officer and
President, Mr. Robert Nichols, the Company's Executive
Vice President and Mr. Brookman March, President of
Altamira, or any material expansion of the Company's
operations could place a significant additional strain
on the Company's limited management resources and could
be materially adverse to the Company's results and
financial condition.
The Common Stock of the Company is Thinly Traded and is
Subject to Volatility
As of August 28, 2009, there were only 1,196,577 shares
of Common Stock of the Company outstanding, of which 433,882
shares were held by the directors and officers of the Company.
The Common Stock of the Company is traded on the Over-the-
Counter Bulletin Board and, historically, has been thinly
traded. There have been a number of trading days during
fiscal 2009 on which no trades of the Company's Common Stock
were reported. Accordingly, the market price for the Common
Stock is subject to great volatility.
Item 1B. Unresolved Staff Comments
None.
Item 2. Properties.
The Company's executive offices and principal
manufacturing facility comprising approximately 25,000
square feet for its Benchtop Laboratory Equipment Operations,
is located in Bohemia, New York and held pursuant to a lease
expiring in January 2015. The Company's Catalyst Research
Instruments Operations are conducted from an approximately 6,600
square foot facility in Pittsburgh, Pennsylvania held pursuant
to a lease expiring in July 2011. See Note 10 to the Financial
Statements in Item 8. The leased facilities are suitable and
adequate for each of the Company's two operations. In the opinion
of management, all properties are adequately covered by insurance.
Item 3. Legal Proceedings.
The Company is not a party to any pending legal proceedings.
Item 4. Submission of Matters to a Vote of Security Holders.
No matters were submitted to a vote of security holders
during the fourth quarter of fiscal 2009.
PART II
Item 5. Market for the Registrant's Common Equity, Related
Stockholder Matters and Issuer Purchase of Equity Securities.
The Company's Common Stock is traded in the over-the-counter
market. The following table sets forth the low and high bid
quotations for each quarter of fiscal 2008 and fiscal 2009, as
reported by the National Association of Securities Dealers, Inc.
Electronic Bulletin Board. Such quotations reflect inter-dealer
prices, without retail mark-up, mark-down or commission and may
not represent actual transactions:
For Fiscal Quarter Ended: Low Bid High Bid
_________________________ _______ ________
09/30/07 2.70 3.35
12/31/07 3.11 3.95
03/31/08 3.30 3.85
06/30/08 3.06 4.15
09/30/08 2.75 3.75
12/31/08 1.75 2.89
03/31/09 1.49 2.50
06/30/09 1.26 1.95
(a) As of August 28, 2009, there were 528 record holders of
the Company's Common Stock.
(b) On January 15, 2009, the Company paid a cash dividend of
$.08 per share to stockholders of record on October 27, 2008.
On January 14, 2008, the Company paid a cash dividend of $.07
per share to stockholders of record on October 18, 2007. The
Company is not subject to any agreement which prohibits or restricts
the Company from paying dividends on its Common Stock.
Item 7. Management's Discussion and Analysis of Financial
Condition and Results of Operations.
Forward-Looking statements. Certain statements contained
in this report are not based on historical facts, but are
forward-looking statements that are based upon various assumptions
about future conditions. Actual events in the future could differ
materially from those described in the forward-looking information.
Numerous unknown factors and future events could cause such
differences, including but not limited to, product demand, market
acceptance, success of marketing strategy, success of expansion
efforts, impact of competition, adverse economic conditions, and
other factors affecting the Company's business that are beyond the
Company's control, which are discussed elsewhere in this report.
Consequently, no forward-looking statement can be guaranteed. The
Company undertakes no obligation to publicly update forward-looking
statements, whether as a result of new information, future events
or otherwise. This Management's Discussion and Analysis of Financial
Condition and Results of Operations should be read in conjunction with
our financial statements and the related notes included elsewhere in
this report.
Overview. The Company's income before income taxes
decreased by $140,600 (26%) to $403,900 for fiscal 2009 compared to
$544,500 for fiscal 2008 mainly as a result of the loss incurred by
the Catalyst Research Instruments Operations of $33,700 for fiscal 2009
compared to a profit of $193,900 for fiscal 2008, which was partially
offset by the increase in profit generated by the Benchtop Laboratory
Equipment Operations. The loss incurred by the Company's Catalyst
Research Instruments Operations was due to lower sales and higher
research and development expenses. The Company's Benchtop Laboratory
Equipment Operations benefitted from an increase in foreign sales
and lower operating expenses.
While the slowdown in the nation's economy has had to date an
adverse effect on the Company's Catalyst Research Instruments Operations,
no representation can be made as to the materiality of the adverse effect
and the duration of the slowdown with respect to the Company's future
results particularly as to its effect on the availability and amount of
the research grants and project funding for purchases by customers of
catalyst research instruments.
Results of Operations. Net sales for fiscal 2009 decreased by
$680,300 (10.2%) to $5,989,100 as compared with $6,669,400 for fiscal
2008. Net sales of the Benchtop Laboratory Equipment Operations
increased by $77,900 (2.1%) primarily due to increased sales to
overseas customers, which more than offset a decrease in domestic
sales. During fiscal 2009 the Company's largest distributor
discontinued the inclusion of the Company's Benchtop Laboratory
Equipment products in its new catalog which was released in January
2009. While the products continue to be sold through the
distributor's website, Company placed advertisements in the
distributor's interim publications, and direct customer requests,
no assurances can be given that there will not be a further
reduction in the amount of sales to the distributor. To mitigate
the material adverse effect of the catalog discontinuance, the
Company has increased advertisements placed in the distributor's
interim publications, hired a new sales manager who is working
with this distributor's sales representatives, and increased its
efforts to sell through other distributors.
Net sales of the Catalyst Research Instruments Operations
decreased by $758,200 (26.2%) due to a reduction in large orders
which the Company believes are the result of a reduction in
government or third party funding for potential customers. Sales
of this segment's products are comprised of a small number of large
orders, typically averaging more than $100,000 each. As of June
30, 2009, there was a backlog of orders aggregating $1,216,600 for
Catalyst Research Instrument products, all of which the Company
anticipates filling by December 31, 2009, compared with $770,900
as of June 30, 2008.
The gross profit percentage for fiscal 2009 increased to
36.6% compared to 36.0% for fiscal 2008, due to slightly higher
gross margins for both the Benchtop Laboratory Operations and the
Catalyst Research Instruments Operations.
General and administrative expenses for fiscal 2009
decreased by $66,300 (6.8%) to $909,400 from $975,700 for fiscal
2008, principally the result of lower expenses with respect to the
Benchtop Laboratory Equipment Operations, including those incurred
for Sarbanes-Oxley Act compliance.
Selling expenses for fiscal 2009 decreased by $116,700
(21.1%) to $435,500 from $552,200 for fiscal 2008, primarily as a
result of lower sales commissions paid with respect to Catalyst
Research Instruments Operations sales.
Research and development expenses for fiscal 2009 were
$452,600, an increase of $58,000 (14.7%) from $394,600 for fiscal
2008, mainly due to the increase in new product development by
the Catalyst Research Instruments Operations.
Other income decreased by $56,300 (88.0%) to $7,700 for
fiscal 2009 from $64,000 for fiscal 2008, reflecting smaller cash
and investment balances for fiscal 2009, and the write-off of an
asset related to the Catalyst Research Instruments Operations.
Income tax expense for fiscal 2009 was $84,400 compared to
$153,000 for fiscal 2008 due to lower income.
As a result of the foregoing, net income for fiscal 2009
was $319,500, a decrease of $72,000 (18.4%) from $391,500 for
fiscal 2008.
Liquidity and Capital Resources. Cash and cash equivalents
decreased by $327,100 (30.7%) to $738,400 as of June 30, 2009 from
$1,065,500 as of June 30, 2008.
The Company reflected $47,800 in net cash used in operating
activities for fiscal 2009 compared to $867,200 of net cash
provided by operating activities for fiscal 2008. The significant
decrease was due to the significantly lower accounts receivable
balances at the end of fiscal 2008, due to the fact that Altamira
had received a substantial amount of cash advances from its
customers towards orders shipped at the end of fiscal 2008.
Cash used in financing activities increased to $91,200
compared to $17,300 for fiscal 2008 mainly due to lower proceeds
from stock option exercises.
The Company's working capital of $2,983,100 as of June 30,
2009 was $206,900 (7.5%) higher than the working capital of
$2,776,200 as of June 30, 2008, the result mainly of the Company's
profitability.
The Company has available for its working capital needs, a
one-year line of credit of $500,000 with Capital One Bank, N.A.
expiring in November 2009. During fiscal 2009, the Company made
borrowings of $50,000 under this line which were repaid by year
end. Advances under the line are secured by the Company's assets
and bear interest at the bank's prime rate. Management believes
that the Company will be able to meet its cash flow needs during
the 12 months ending June 30, 2010 from its available financial
resources including its cash and investment securities, and
operations.
Capital Expenditures. During fiscal 2009, the Company
incurred $66,600 in capital expenditures, which the Company
expects will be the approximate level during the fiscal year
ending June 30, 2010.
Off-Balance Sheet Arrangements. None.
Item 8. Financial Statements and Supplementary Data.
The Financial Statements required by this item are attached
hereto on pages F1-F24.
Item 9. Changes In and Disagreements With Accountants on
Accounting and Financial Disclosure.
Not applicable.
Item 9A. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures. As
of the end of the period covered by this report, based on an
evaluation of the Company's disclosure controls and procedures
(as defined in Rules 13a-15(e) and 15d-15(e) under the Securities
Exchange Act of 1934), the Chief Executive and Chief Financial
Officer of the Company has concluded that the Company's disclosure
controls and procedures are effective to ensure that information
required to be disclosed by the Company in its Exchange Act reports
is recorded, processed, summarized and reported within the applicable
time periods specified by the SEC's rules and forms. The Company also
concluded that information required to be disclosed in such reports
is accumulated and communicated to the Company's management,
including its principal executive and principal financial officer,
as appropriate to allow timely decisions regarding required
disclosure.
Management's Annual Report on Internal Control Over
Financial Reporting. Management is responsible for establishing
and maintaining adequate internal control over the Company's
financial reporting, as such term is defined in Securities Exchange
Act Rule 13a-15(f). The Company's internal controls over financial
reporting are designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted
accounting principles.
The Chief Executive and Chief Financial Officer of the Company
conducted an evaluation of the effectiveness of the Company's internal
controls over financial reporting as of June 30, 2009 based on the
criteria set forth by the Committee of Sponsoring Organizations of
the Treadway Commission (COSO) in Internal Control Integrated
Framework.
Based on the assessment of the Company's Chief Executive and
Chief Financial Officer of the Company, it was concluded that as of
June 30, 2009, the Company's internal controls over financial
reporting were effective based on these criteria.
This annual report does not include an attestation report of
the Company's registered public accounting firm regarding internal
control over financial reporting. Management's report was not
subject to attestation by the Company's registered public accounting
firm pursuant to temporary rules of the Securities and Exchange
Commission that permit the Company to provide only management's
report in this annual report.
Changes in Internal Control Over Financial Reporting. There
was no change in the Company's internal controls over financial
reporting that occurred during the most recent fiscal quarter that
materially affected or is reasonably likely to materially affect the
Company's internal controls over financial reporting.
Item 9B. Other Information.
Not applicable.
PART III
Item 10. Directors, Executive Officers and Corporate Governance.
Directors
The Company has the following six Directors:
Arthur M. Borden, Esq. (age 89), a Director since 1974, has
been counsel to the law firm of Katten Muchin Rosenman LLP (formerly
Rosenman & Colin) during the past five years. He is a director of
Supreme Industries, Inc., a nationwide manufacturer of specialized
truck bodies.
Joseph G. Cremonese (age 73), a Director since November 2002
and Chairman of the Board since February 2006, has been a marketing
consultant to the Company since 1996. Mr. Cremonese has been since
1991, President of Laboratory Innovation Company, Ltd., which is a
vehicle for technology transfer and consulting services for companies,
including the Company, engaged in the production and sale of products
for science and biotechnology. Since March 2003, he has been a
director of and consultant to Proteomics, Inc., a producer of
recombinant proteins for medical research. Prior to 1991, he
had been employed by Fisher Scientific, the largest U.S. distributor
of laboratory equipment.
Joseph I. Kesselman (age 84), a Director since 1961 and
Chairman of the Board from August 2002 until his resignation in
February 2006, has been for more than five years a consultant to
various corporations, including Nuclear and Environmental Protection
Inc. and Hopare Holding, S.A. (a Swiss company), both companies of
which he had been a director, and Perrot Duval Management, S.H.
(a Swiss management company).
Roger B. Knowles (age 84), a Director since 1965, is retired.
During the past five years he has been involved in liquidating
various real estate and manufacturing concerns.
Grace S. Morin (age 61), a Director since December 4, 2006,
had been President, Director and principal stockholder of Altamira
Instruments, Inc. from December 2003 until its acquisition in
November 2006 by the Company. Ms. Morin had been employed
by Altamira to supervise its administrative functions at the
Pittsburgh, Pennsylvania facility as a full-time employee through
March 31, 2009 and since that date as a part-time consultant.
Prior to December 2003, she was a general business consultant for
two years, and prior to that a member of senior management of a
designer of gas flow environmental engineered products for
approximately four years.
James S. Segasture (age 73), a Director since 1991, has
been a private investor since February 1990.
The Directors are elected to three-year staggered terms.
The current terms of the Directors expire at the annual meeting of
stockholders of the Company to be held at the annual meeting
following: the fiscal year ended June 30, 2009 - two Directors
(Messrs. Borden and Segasture, Class A) the fiscal year ending
June 30, 2010 - two Directors (Mr. Kesselman and Ms. Morin,
Class B) and the fiscal year ending June 30, 2011 - two Directors
(Messrs. Cremonese and Knowles, Class C).
Board Committees
Joseph I. Kesselman and James S. Segasture have been
the sole members of the Company's Stock Option Committee, the
members of which serve at the discretion of the Board. The
Committee administers the Company's 2002 Stock Option Plan ("2002
Plan").
Grace S. Morin, Joseph I. Kesselman, and James S.
Segasture have been the members of the Company's Compensation
Committee serving at the discretion of the Board. The Committee
administers the Company's compensation policies.
The Board of Directors acts as the Company's Audit
Committee.
The Company does not have a financial expert on the Audit
Committee as defined by the Securities and Exchange Commission,
however, the Company believes that the members of the Audit
Committee have sufficient knowledge to properly evaluate and
analyze the Company's financial statements.
Executive Officers
Helena R. Santos, CPA (age 45), employed by the Company
since 1994, has served since August 2002 as President, Chief
Executive Officer and Treasurer. Previously she served as Vice
President, Controller from 1997 and as Secretary from May 2001.
Ms. Santos was an internal auditor with a major defense
contractor from March 1991 to April 1994. She had been previously
employed in public accounting.
Robert P. Nichols (age 48), employed by the Company since
February 1998, has served since August 2002 as Executive Vice
President. Previously, he had been since May 2001 Vice President,
Engineering. Prior to joining the Company, Mr. Nichols was an
Engineer Manager with Bay Side Motion Group, a precision motion
equipment manufacturer from January 1996 to February 1998.
Brookman P. March (age 64) has been Director of Sales and
Marketing since November 30, 2006 and President since July 2008
of Altamira, which conducts the Catalyst Research Instruments
operation. He had been Vice President and a Director of Altamira
from December 2003 until it was acquired by the Company. Mr.
March is the husband of Ms. Morin, a Director.
Section 16(a) Beneficial Ownership Reporting Compliance
The Company believes that, for the year ended June 30, 2009,
its officers, directors and 10% stockholders timely complied with
all filing requirements of Section 16(a) of the Securities Exchange
Act of 1934, as amended.
Code of Ethics
We have adopted a code of ethics that applies to our
Executive Officers and Directors. A copy of the code of ethics
can be found on our website at www.scientificindustries.com.
Item 11. Executive Compensation.
The following table summarizes all compensation paid by the
Company to each of the executive officers set forth in the table
for the two fiscal years ended June 30, 2009 and 2008. No other
executive officer earned in excess of $100,000 in any of such
fiscal periods.
The Compensation Committee reviews and recommends to the
Board of Directors the compensation to be paid to each executive
officer. In making a determination, the Committee and the Board
give material consideration to the Company's results of operations
and financial condition, competitive factors and the Company's
resources. The compensation at times includes grants of options
under its stock option plan to the named executives. Each officer
is employed pursuant to a long-term employment agreement, containing
terms proposed by the committee and approved as reasonable by the
Board of Directors. The Board is cognizant that as a relatively
small company, the Company has limited resources and opportunities
with respect to recruiting and retaining key executives.
Accordingly, the Company has relied upon long-term employment
agreements to retain qualified personnel.
SUMMARY COMPENSATION TABLE
_____________________________________________________________
Non-
Equity
Incentive
Name Plan
and Stock Option Comp-
Principal Fiscal Salary Bonus Awards Awards ensation
Position Year ($) ($) ($) ($) ($)
(a) (b) (c) (d) (e) (f) (g)
_____________________________________________________________
Helena R. 2009 125,000 0 0 0 0
Santos, 2008 120,000 10,000 0 0 0
CEO,
President,
CFO
Robert P. 2009 117,500 0 0 0 0
Nichols, 2008 115,000 10,000 0 0 0
Exec.
V. P.
Brookman 2009 112,900 0 0 0 0
P. March, 2008 110,000 0 0 0 0
Director
of Sales
and Market-
ing, and
since July
2008,
President
of
Altamira
_____________________________________________________________
SUMMARY COMPENSATION TABLE (CONTINUED)
_____________________________________________________________
Non-
Qualified
Deferred All
Name Comp- Other
and ensation Comp-
Principal Earnings ensation Total
Position ($) ($) ($)
(a) (h) (i) (j)
_____________________________________________________________
Helena R. 2009 2,500(1) 127,500
Santos, 2008 2,600(1) 132,600
CEO,
President,
CFO
Robert P. 2009 2,350(1) 119,850
Nichols, 2008 2,500(1) 127,500
Exec.
V. P.
Brookman 2009 4,516(1) 117,416
P. March, 2008 4,400(1) 114,400
Director
of Sales
and Market-
ing, and
since July
2008,
President
of
Altamira
_____________________________________________________________
(1)Represents the Company's matching contribution under the
Company's 401(k) Plans.
OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END
_____________________________________________________________
Option Awards
_____________________________________________________________
Number Inactive
Number of Plan
of Securities Awards
Securities Under- Number of
Under- lying Securities
lying Un- Unexercised Underlying Option
exercised Options(#) Unexercised Exercise Option
Options(#) Unexerci- Unearned Price Expiration
Name Exercisable sable Options ($) Date
(a) (b) (c) (d) (e) (f)
______________________________________________________________________
Robert P.
Nichols 5,000 0 0 1.25 10/2012
______________________________________________________________________
No other executive officer had any unexercised options as of June
30, 2009 and no options had been granted to any officer during
fiscal 2009.
Aggregated Option Exercises in Last Fiscal Year and FY-End Option
Values
AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR AND FY-END OPTION VALUES
Number of
Shares of Securities Value of
Common Underlying Unexercised
Stock Unexercised in-the-money
Acquired Options Options
On Value at FY-End (#) at FY-End ($)
Exercise Realized Exercisable/ Exercisable/
Name (#) ($)(1) Unexercisable Unexercisable(1)
________________________________________________________________________
Helena R.
Santos 5,000 3,100 0/0 -
Robert P.
Nichols 8,000 5,000 5,000/0 2,300/0
________________________________________________________________________
(1) Calculated by multiplying the number of shares of Common Stock
subject to options by the difference between: (i) the market price on
date of exercise, and June 30, 2009, respectively, and (ii) the exercise
price.
Employment Agreements
In July 2009, the Company entered into agreements with Ms.
Helena R. Santos and Mr. Robert P. Nichols related to their employment
in their current positions for the 24-month period ending December
31, 2010. Their prior employment agreements expired on December 31,
2008. The agreements provide a base salary for the 12 months ended
December 31, 2009 for Ms. Santos of $130,000 and for Mr. Nichols of
$120,000, plus a $5,000 bonus for each with respect to the first 12
month period. The base salary for each for the 12 months ending
December 31, 2010 is to be determined by the Company's Board of
Directors, but to be not less than the officer's base salary for the
prior 12 month period. No other bonuses were awarded with respect
to fiscal 2009. The bonuses, if any, for the 12 month period ending
December 31, 2010 are also to be determined by the Board of Directors.
A bonus of $10,000 had been awarded and paid to each officer in
fiscal 2008.
The employment agreements for Ms. Santos and Mr. March
contain termination provisions stipulating that if the Company
terminates the employment of the employee other than for death,
disability, or cause (defined as (i) conviction of a felony or (ii)
gross neglect or gross misconduct (including conflict of interest) in
the carrying out of his or her duties under the agreement), the Company
shall pay severance payments equal to one year's salary at the rate
of the compensation at the time of termination, and continue to pay his
or her regular benefits provided by the Company for a period of two
years from termination.
Mr. Brookman P. March is employed by Altamira pursuant to a
24-month employment agreement through November 30, 2010 which may be
extended by mutual consent for an additional 12 month period but not
beyond November 30, 2012. The agreement provides for an annual base
salary of $115,000 for the first 12 month period, and $121,900 for the
second 12 month period, with Altamira having the option to pay the
$6,900 increase in base salary in stock options of the Company
(subject to Mr. March's consent). The agreement also provides for
a bonus in each of the two years at the discretion of Altamira's
Board of Directors. No bonuses have yet been awarded under this
agreement.
Mr. March is the husband of Grace S. Morin, a Director of
the Company and of Altamira and a former principal stockholder of
Altamira.
All employment agreements contain confidentiality and
non-competition covenants.
Directors' Compensation
DIRECTORS' COMPENSATION
FOR THE YEAR ENDED JUNE 30, 2009
Non-
Equity
Fees Incentive
Earned Plan
or Paid Stock Option Comp-
in Cash Awards Awards ensation
Name ($) ($) ($) ($)
(a) (b) (c) (d) (e)
_____________________________________________________________________
Arthur M.
Borden 12,000 0 0 0
Joseph G.
Cremonese 24,000 0 0 0
Joseph I.
Kesselman 12,000 0 0 0
Roger B.
Knowles 12,000 0 0 0
Grace S.
Morin 2,500 0 0 0
James S.
Segasture 12,000 0 0 0
____________________________________________________________________
DIRECTORS' COMPENSATION (CONTINUED)
Changes
in
Pension
Value and
Non- Non-
qualified qualified
Deferred Deferred All
Compens- Comp- Other
ation ensation Comp-
Earnings Earnings ensation Total
Name ($) ($) ($) ($)
(a) (f) (g) (h) (i)
____________________________________________________________________
Arthur M. 0 0 12,000
Borden
Joseph G.
Cremonese 0 36,000(1) 60,000
Joseph I.
Kesselman 0 0 12,000
Roger B.
Knowles 0 0 12,000
Grace S.
Morin 0 10,400(2) 12,900
James S.
Segasture 0 0 12,000
____________________________________________________________________
(1) Represents amount paid to his affiliate pursuant to a marketing
consulting agreement (see Item 12).
(2) Represents compensation received for her administrative services
as a consultant for Altamira but does not include her compensation as
a full-time employee through March 31, 2009 (See Items 12 and 13).
The Company pays each Director who is not an employee of
the Company or a subsidiary a quarterly retainer fee of $1,500 and
$1,000 for each meeting attended. In addition, the Company reimburses
each Director for out-of-pocket expenses incurred in connection with
attendance at board meetings in the amount of $50 or the Director's
itemized expenses, whichever is greater. Mr. Cremonese, as Chairman
of the Board since February 2006, receives an additional fee of
$1,000 per month. During fiscal 2009, the fees to non-employee
Directors aggregated $120,900, including the consulting fees paid
to Mr. Cremonese's affiliate, and since April 1, 2009, to Ms. Morin.
She also received $49,200 as an administrative employee of Altamira
for the nine months ended March 31, 2009.
Pursuant to the Company's 1992 Stock Option Plan ("1992
Plan") options to purchase 3,000 shares of Common Stock at the then
fair market value were granted to each non-employee director who was
on the Board of Directors on the first business day of each March, in
1993, 1994, 1995, and 1996, namely Messrs. Borden, Kesselman, Knowles
and Segasture. In addition, in December 1997 and through December 2002
the Board of Directors granted under the 1992 Plan annually options to
purchase 4,000 shares of Common Stock to each of them exercisable at
the fair market value on the date of grant. Accordingly, as of June
30, 2009, the Company had granted under the 1992 Plan to the foregoing
four non-employee Directors options to purchase an aggregate of 128,000
shares of Common Stock, or options to purchase 32,000 shares of Common
Stock to each. The fair market value per share of Common Stock on the
dates of grant ranged from $0.50 for options granted in 1993 to $2.40 in
2002. As of June 30, 2009, options under the 1992 Plan with respect to
90,000 shares had been exercised by the Directors and with respect to
10,000 shares had expired. In addition, they had exercised options
with respect to 48,000 shares granted to them prior to the adoption
of the 1992 Plan.
Under the Company's 2002 Plan, none of the Directors at
the time of the adoption by the Board of Directors of the 2002 Plan
(subsequently approved by stockholders) were eligible to receive option
grants thereunder. Mr. Joseph G. Cremonese who was elected a Director
at the 2002 Annual Meeting of Stockholders, was granted on December 1,
2003 a ten-year option to purchase 5,000 shares of Common Stock at the
fair market value of $1.35 per share, on February 20, 2007 a ten-year
option to purchase 5,000 shares of Common Stock at the fair market value
of $3.10 per share. The options had a fair value of $10,100 of which
$2,000 was recognized as expense in fiscal 2009. Neither option has been
exercised to date.
Item 12. Security Ownership of Certain Beneficial Owners and
Management and Related
Stockholder Matters.
The following table sets forth, as of June 30, 2009,
the number of shares of Common Stock beneficially owned by (i)
each person known to the Company to beneficially own more than
5% of the Common Stock, (ii) each director of the Company, (iii)
each named executive officer of the Company, and (iv) all directors
and executive officers as a group. Shares not outstanding but
deemed beneficially owned by virtue of the right of any individual
to acquire shares within 60 days are treated as outstanding only
when determining the amount of and percentage of Common Stock owned
by such individual. Each person has sole voting and investment power
with respect to the shares shown, except as noted. Except as indicated
in the table, the address for each of the following is c/o Scientific
Industries, Inc., 70 Orville Drive, Bohemia, New York 11716.
Amount and
Name Nature of Beneficial Ownership % of Class
_______________________________________________________________________
Spectrum Laboratories, Inc. 124,736 (1) 10.5%
18617 Broadwick Street
Rancho Dominquez, CA 90220
Lowell A. Kleiman 139,581 (2) 11.7%
16 Walnut Street
Glen Head, NY 11545
Arthur M. Borden 56,740 (3) 4.7%
Joseph G. Cremonese 44,597 (4) 3.7%
Joseph I. Kesselman 64,120 (5) 5.3%
Roger B. Knowles 4,000 (6) .3%
Grace S. Morin 82,950 7.0%
James S. Segasture 187,250 (7) 15.6%
Helena R. Santos 15,779 1.3%
Robert P. Nichols 21,446 (8) 1.8%
Brookman P. March 82,950 (9) 7.0%
All directors and executive
officers as a group (8 persons) 476,882 (10) 40%
(1) Based on information reported on Schedule 13G filed with the
Securities and Exchange Commission on June 15, 2009.
(2) Based on information reported in his Schedule 13D filed with
the Securities and Exchange Commission on October 30, 2002.
(3) Includes 12,000 shares issuable upon exercise of options.
(4) 34,597 shares are owned jointly with his wife and 10,000
shares are issuable upon exercise of options; does not include
additional 10,000 shares issuable upon exercise of options
granted on September 17, 2009.
(5) Includes 8,000 shares issuable upon exercise of options,
735 shares owned jointly with his wife, and 12,000 shares owned
by his wife.
(6) Represents shares issuable upon exercise of options.
(7) Includes 4,000 shares issuable upon exercise of options
and 493 shares owned by his wife.
(8) Includes 5,000 shares issuable upon exercise of options.
(9) Represents shares owned by his wife, Ms. Morin.
(10)Includes 43,000 shares issuable upon exercise of options.
EQUITY COMPENSATION PLAN INFORMATION
The following information with respect to Company options, warrants and
rights is as of June 30, 2009.
_________________________________________________________________
Number of Securities
to be Issued Upon Weighted-Average
Exercise of Exercise Price of
Outstanding Options, Outstanding Options,
Warrants and Rights Warrants and Rights ($)
Plan Category (a) (b)
_________________________________________________________________
Equity
Compensation
plans approved by
security holders 44,501 2.09
Equity
Compensation
plans not approved
by security holders N/A N/A
_________________________________________________________________
Total 44,501 2.09
_________________________________________________________________
EQUITY COMPENSATION PLAN INFORMATION (CONTINUED)
_________________________________________________________________
Number of Securities
Remaining Available
for
Future Issuance
Under
Equity Compensation
Plans (Excluding
Securities Reflected
in Column (a)
Plan Category (c)
_________________________________________________________________
Equity
Compensation
plans approved by
security holders 107,834
Equity
Compensation
plans not approved
by security holders N/A
_________________________________________________________________
Total 107,834
_________________________________________________________________
Item 13. Certain Relationships and Related Transactions, and
Director Independence.
Mr. Joseph G. Cremonese, who was elected a Director in
November 2002, through his affiliate, Laboratory Innovation Company,
Ltd., has been providing independent marketing consulting services
to the Company for approximately ten years. The services have
been rendered since January 1, 2003 pursuant to a consulting
agreement which was amended and restated in March 2007 and extended
in September 2009 through December 31, 2010. The agreement as amended
and restated provides that Mr. Cremonese and his affiliate render, at
the request of the Company, marketing consulting services of at least
60, but not more than 96, days per year at the rate of $600 per day
with a monthly payment of $3,000, with the Company's obligation
reduced to the extent the consulting services are less than 60 days
for the 12 month period. The agreement contains confidentiality and
non-competition covenants. During fiscal 2009, the Company paid an
aggregate of $36,000 for the consulting services.
Ms. Grace S. Morin, was elected a Director in December 2006
in connection with the sale of her 90.36% ownership interest in
Altamira to the Company in November 2006. Under the purchase agreement
Ms. Morin is to receive (in addition to $361,000 in cash paid and
an aggregate of 112,950 shares of the Company's Common Stock issued at
the time of acquisition) an amount equal to her 90.36% share of 5%
of net sales of Altamira for each of five designated periods, subject
to possible adjustment. The first period ran from December 1, 2006
through June 30, 2007, the second, third, and fourth periods are the
12 months ended June 30, 2008, June 30, 2009, and June 30, 2010 and
the fifth period runs from July 1, 2010 to November 30, 2010. Ms.
Morin received contingent consideration of $59,700 for the first
period, $131,000 for the second period, and $97,000 for the third
period. She also received $36,400 as an agreed upon reimbursement
for the Company's treatment of the transaction as a purchase of
assets for tax purposes.
Up until March 31, 2009, Ms. Morin had been employed by
Altamira as an administrative employee. Since April 1, 2009, she
provides consulting services on a part-time basis pursuant to an
agreement expiring March 31, 2011 at the rate of $85 per hour. The
agreement contains confidentiality and non-competition covenants.
During fiscal 2009, Altamira paid her $10,400 for the consulting
services from April 1, 2009 to June 30, 2009 in addition to
compensation as an employee for the period July 1, 2008 to March
31, 2009.
Item 14. Principal Accountant Fees and Services.
The Company incurred for the services of Nussbaum Yates
Berg Klein & Wolpow, LLP for fiscal 2009 and fiscal 2008: audit
fees of approximately $38,000 and $37,000, respectively, in
connection with the audit of the Company's financial statements;
$4,000 for each of fiscal 2009 and fiscal 2008 for the preparation
of the Company's corporate tax returns; $9,600 and $9,000
respectively, in connection with the quarterly reviews for fiscal
2009 and fiscal 2008, respectively. In addition, the Company paid
the firm $12,600 in fiscal 2008 for services rendered primarily
in connection with the acquisition of Altamira Instruments, Inc.
There were no other audit related fees or other fees paid to the
firm.
In approving the engagement of the independent registered
public accounting firm to perform the audit and non-audit services,
the Board of Directors as the Company's audit committee evaluates
scope and cost of each of the services to be performed including a
determination that the performance of the non-audit services will
not affect the independence of the firm in the performance of the
audit services.
Part IV
Item 15. Exhibits and Financial Statement Schedule.
Financial Statements and Financial Statement Schedules. The
required financial statements of the Company are attached hereto
on pages F1-F24.
Exhibits. The following Exhibits are filed as part of this report
on Form 10-K:
Exhibit Number Exhibit
______________ ______________________________
3 Articles of Incorporation and By-Laws:
3(a) Certificate of Incorporation of the Company as amended.
(Filed as Exhibit 1(a-1) to the Company's General Form
for Registration of Securities on Form 10 dated February
14, 1973 and incorporated by reference thereto.)
3(b) Certificate of Amendment of the Company's Certificate
of Incorporation, as filed on January 28, 1985.
(Filed as Exhibit 3(a) to the Company's Annual Report on
Form 10-K for the fiscal year ended June 30, 1985 and
incorporated by reference thereto.)
3(c) By-Laws of the Company, as restated and amended.
(Filed as Exhibit 3(ii) to the Company's Current Report
on Form 8-K filed on January 6, 2003 and Exhibit 3(ii)
to the Company's Current Report on Form 8-K filed
on December 5, 2007 and incorporated by reference thereto).
4 Instruments defining the rights of security holders:
4(a) 2002 Stock Option Plan (Filed as Exhibit 99-1 to the
Company's Current Report on Form 8-K filed on November
25, 2002 and incorporated by reference thereto.
10 Material Contracts:
10(a) Lease between Registrant and AIP Associates,
predecessor-in-interest of current lessor, dated
October, 1989 with respect to Company's offices and
facilities in Bohemia, New York. (Filed as Exhibit
10(a) to the Company's Form 10-KSB filed on September
28, 2005 and incorporated by reference thereto).
10(a)-1 Amendment to lease between Registrant and REP A10 LLC,
successor in interest of AIP Associates, dated September
1, 2004 (Filed as Exhibit 10A-1 to the Company's Current
Report on Form 8-K filed on September 2, 2004, and
incorporated by reference thereto).
10(a)-2 Second amendment to lease between Registrant and REP
A10 LLC dated November 5, 2007. (Filed as Exhibit
10A-1 to the Company's Current Report on Form 8-K
filed on November 8, 2007, and incorporated by
reference thereto).
10(b) Employment Agreement dated January 1, 2003, by and
between the Company and Ms. Santos (Filed as Exhibit
10(a) to the Company's Current Report on Form 8-K
filed on January 22, 2003, and incorporated by
reference thereto).
10(b)-1 Employment Agreement dated September 1, 2004, by and
between the Company and Ms. Santos (Filed as Exhibit
10A-1 to the Company's Current Report on Form 8-K filed
on September 1, 2004, and incorporated by reference
thereto).
10(b)-2 Employment Agreement dated December 29, 2006, by and
between the Company and Ms. Santos (Filed as Exhibit 10A-1
to the Company's Current Report on Form 8-K filed on
December 29, 2006, and incorporated by reference thereto).
10(b)-3 Employment Agreement dated July 31, 2009 by and between
the Company and Ms. Santos (Filed as Exhibit 10A-1 to the
Company's Current Report on Form 8-K filed on August 7, 2009,
and incorporated by reference thereto).
10(c) Employment Agreement dated January 1, 2003, by and between
the Company and Mr. Robert P. Nichols (Filed as Exhibit
10A-1 to the Company's Current Report on Form 8-K filed
on January 22, 2003, and incorporated by reference
thereto).
10(c)-1 Employment Agreement dated September 1, 2004, by and
between the Company and Mr. Nichols (Filed as Exhibit 10A-1
to the Company's Current Report on Form 8-K filed on
September 1, 2004, and incorporated by reference thereto).
10(c)-2 Employment Agreement dated December 29, 2006, by and
between the Company and Mr. Nichols (Filed as Exhibit 10A-1
to the Company's Current Report on Form 8-K filed on
December 29, 2006, and incorporated by reference thereto).
10(c)-3 Employment Agreement dated July 31, 2009 by and between the
Company and Mr. Nichols (filed as Exhibit 10A-2 to the
Company's Current Report on Form 8-K filed on August 7,
2009, and incorporated by reference thereto).
10(d) Consulting Agreement dated January 1, 2003 by and between
the Company and Mr. Cremonese and his affiliate, Laboratory
Innovation Company, Ltd., (Filed as Exhibit 10(b) to the
Company's Current Report on Form 8-K filed on January 6,
2003, and incorporated by reference thereto).
10(d)-1 Amended and Restated Consulting Agreement dated March 22,
2005, by and between the Company and Mr. Cremonese and
Laboratory Innovation Company, Ltd., (Filed as Exhibit
10A-1 to the Company's Current Report on Form 8-K filed
on March 23, 2005, and incorporated by reference thereto).
10(d)-2 Second Amended and Restated Consulting Agreement dated
March 15, 2007, by and between the Company and Mr.
Cremonese and Laboratory Innovation Company Ltd., (Filed
as Exhibit 10A-1 to the Company's Current Report on Form 8-K
filed on March 16, 2007, and incorporated by reference
thereto).
10(d)-3 Third Amended and Restated Consulting Agreement dated
September 23, 2009, by and between the Company and Mr.
Cremonese and Laboratory Innovation Company, Ltd.
10(e) Sublicense from Fluorometrix Corporation (Filed as Exhibit
10(a)1 to the Company's Current Report on Form 8-K filed
on June 14, 2006, and incorporated by reference thereto).
10(f) Stock Purchase Agreement, dated as of November 30, 2006,
by and among the Company and Grace Morin, Heather H. Haught
and William D. Chandler (Filed as Exhibit 2.1 to the
Company's Current Report on Form 8-K filed on December 5,
2006, and incorporated by reference thereto).
10(g) Escrow Agreement, dated as of November 30, 2006, by and
among the Company and Grace Morin, Heather H. Haught and
William D. Chandler (filed as Exhibit 10(a) to the
Company's Current Report on Form 8-K filed on December 5,
2006, and incorporated by reference thereto).
10(h) Registration Rights Agreement, dated as of November 30,
2006, by and among the Company and Grace Morin, Heather
H. Haught and William D. Chandler (filed as Exhibit 10(b)
to the Company's Current Report on Form 8-K filed on
December 5, 2006, and incorporated by reference
thereto).
10(i) Employment Agreement, dated as of November 30, 2006,
between Altamira Instruments, Inc. and Brookman P. March
(Filed as Exhibit 10(c) to the Company's Current Report on
Form 8-K filed on December 5, 2006, and incorporated by
reference thereto).
10(i)-1 Employment Agreement, dated October 30, 2008, between
Altamira Instruments, Inc. and Brookman P. March (Filed
as Exhibit 10A-2 to the Company's Current Report on Form
8-K filed on October 30, 2008, and incorporated by reference
thereto).
10(j) Indemnity Agreement, dated as of April 13, 2007 by and
among the Company and Grace Morin, Heather H. Haught and
William D. Chandler (Filed as Exhibit 10(j) to the Company's
Form 10-KSB filed on September 28, 2007 and incorporated
by reference thereto).
10(k) Lease between Altamira Instruments, Inc. and Allegheny
Homes, LLC, with respect to the Company's Pittsburgh,
Pennsylvania facilities (Filed as Exhibit 10(k) to the
Company's Form 10-KSB filed on September 28, 2007 and
incorporated by reference thereto).
10(l) Line of Credit Agreements dated October 30, 2008, by and
among the Company and Capital One, N.A. (Filed as
Exhibits 10-A1(a) through (f) to the Company's Current
Report on Form 8-K filed on October 30, 2008, and
incorporated by reference thereto).
10(m) Consulting Agreement dated April 1, 2009 by and between
the Company and Grace Morin (Filed as Exhibit 10A-1 to
the Company's Current Report on Form 8-K filed on April
1, 2009, and incorporated by reference thereto).
14 Code of Ethics (Filed as Exhibit 14 to the Company's
Form 10-KSB filed on September 28, 2007 and incorporated
by reference thereto).
21 Subsidiaries of the Registrant
Scientific Packaging Industries, Inc., a New York
corporation, is a wholly-owned inactive subsidiary of
the Company.
Altamira Instruments, Inc., a Delaware Corporation, is
a wholly-owned subsidiary of the Company since November
30, 2006.
31.1 Certification of Chief Executive Officer and Chief
Financial Officer pursuant to Section 302 of Sarbanes-
Oxley Act of 2002.
32.1 Certification of Chief Executive Officer and Chief
Financial Officer pursuant to Section 906 of Sarbanes-
Oxley Act of 2002.
SIGNATURES
Pursuant to the requirements of Section13 or 15(d) of the
Securities Exchange Act of 1934, the registrant caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized.
SCIENTIFIC INDUSTRIES, INC.
___________________________
(Registrant)
/s/ Helena R. Santos
____________________________
Helena R. Santos
President, Chief Executive Officer, Treasurer
Chief Financial and Principal Accounting Officer
Date: September 24, 2009
Pursuant to the requirements of the Securities Exchange Act
of 1934, this report has been signed below by the following persons on
behalf of the registrant and in the capacities and on the dates
indicated.
Name Title Date
____ _____ ____
/s/ Arthur M. Borden Director September 24, 2009
Arthur M. Borden
/s/ Joseph G. Cremonese Chairman of the Board September 24, 2009
Joseph G. Cremonese
/s/ Joseph I. Kesselman Director September 24, 2009
Joseph I. Kesselman
/s/ Roger B. Knowles Director September 24, 2009
Roger B. Knowles
/s/ Grace S. Morin Director September 24, 2009
Grace S. Morin
/s/ James S. Segasture Director September 24, 2009
James S. Segasture
________________________________________________________________________
SCIENTIFIC INDUSTRIES, INC.
AND SUBSIDIARIES
YEARS ENDED JUNE 30, 2009 AND 2008
FINANCIAL STATEMENTS AND REPORT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
YEARS ENDED JUNE 30, 2009 AND 2008
Page
____
Report of independent registered public accounting firm F-1
Consolidated financial statements:
Balance sheets F-2
Statements of income F-3
Statements of shareholders' equity F-4
Statements of cash flows F-5
Notes to financial statements F-6 - F-24
Report of Independent Registered Public Accounting Firm
_______________________________________________________
Board of Directors and Shareholders
Scientific Industries, Inc. and Subsidiaries
Bohemia, New York
We have audited the accompanying consolidated balance sheets of
Scientific Industries, Inc. and subsidiaries as of June 30, 2009
and 2008, and the related consolidated statements of income,
shareholders' equity and cash flows for the years then ended.
These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these
financial statements based on our audits.
We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are
free of material misstatement. The Company is not required to
have, nor were we engaged to perform, an audit of its internal
control over financial reporting. Our audit included consideration
of internal control over financial reporting as a basis for designing
audit procedures that are appropriate in the circumstances, but not
for the purpose of expressing an opinion on the effectiveness of the
Company's internal control over financial reporting. Accordingly, we
express no such opinion. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial
statements, assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide
a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to
above present fairly, in all material respects, the consolidated
financial position of Scientific Industries, Inc. and subsidiaries
as of June 30, 2009 and 2008, and the consolidated results of their
operations and their cash flows for the years then ended in conformity
with accounting principles generally accepted in the United
States of America.
/s/ Nussbaum Yates Berg Klein & Wolpow, LLP
___________________________________________
Nussbaum Yates Berg Klein & Wolpow, LLP
Melville, New York
September 24, 2009
F-1
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
JUNE 30, 2009 AND 2008
ASSETS
2009 2008
__________ __________
Current assets:
Cash and cash equivalents $ 738,400 $1,065,500
Investment securities 605,500 682,400
Trade accounts receivable, less
allowance for doubtful accounts
of $11,600 in 2009 and 2008 806,700 454,800
Inventories 1,598,000 1,521,400
Prepaid and other current assets 91,600 84,700
Deferred taxes 63,400 31,400
---------- ----------
Total current assets 3,903,600 3,840,200
Property and equipment, net 241,200 247,400
Intangible assets, net 330,900 454,600
Goodwill 265,400 158,400
Other 25,700 46,000
Deferred taxes 64,200 30,200
---------- ----------
Total assets $4,831,000 $4,776,800
========== ==========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 137,400 $ 241,800
Customer advances 359,600 379,300
Accrued expenses and taxes 423,500 442,900
---------- ----------
Total current liabilities 920,500 1,064,000
---------- ----------
Shareholders' equity:
Common stock, $.05 par value;
authorized 7,000,000 shares; issued
1,212,379 and 1,201,154 shares in
2009 and 2008 60,600 60,000
Additional paid-in capital 1,514,300 1,507,000
Accumulated other comprehensive loss,
unrealized holding loss on investment
securities (79,600) (44,400)
Retained earnings 2,467,600 2,242,600
--------- ---------
3,962,900 3,765,200
Less common stock held in treasury
at cost, 19,802 shares 52,400 52,400
--------- ---------
Total shareholders' equity 3,910,500 3,712,800
--------- ---------
Total liabilities and
shareholders' equity $4,831,000 $4,776,800
========== ==========
See notes to consolidated financial statements.
F-2
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
YEARS ENDED JUNE 30, 2009 AND 2008
2009 2008
___________ ___________
Net sales $ 5,989,100 $ 6,669,400
Cost of sales 3,795,400 4,266,400
----------- -----------
Gross profit 2,193,700 2,403,000
----------- -----------
Operating expenses:
General and administrative 909,400 975,700
Selling 435,500 552,200
Research and development 452,600 394,600
----------- -----------
1,797,500 1,922,500
----------- -----------
Income from operations 396,200 480,500
----------- -----------
Other income:
Interest income 26,100 51,900
Other income (expense), net (18,400) 12,100
----------- -----------
7,700 64,000
----------- -----------
Income before income taxes 403,900 544,500
----------- -----------
Income tax expense (benefit):
Current 141,100 196,600
Deferred (56,700) (43,600)
----------- -----------
84,400 153,000
----------- -----------
Net income $ 319,500 $ 391,500
=========== ===========
Basic earnings per common share $ .27 $ .34
=========== ===========
Diluted earnings per common share $ .26 $ .32
=========== ===========
Weighted average common shares
outstanding 1,184,884 1,159,494
=========== ===========
Weighted average common shares outstanding,
assuming dilution 1,209,910 1,206,236
=========== ===========
See notes to consolidated financial statements.
F-3
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
YEARS ENDED JUNE 30, 2009 AND 2008
Common Stock Additional Accumulated
______________ Paid-in Other Compr-
Shares Amount Capital ehensive Loss
_______ _______ __________ _____________
Balance, July 1, 2007 1,165,154 $58,200 $1,428,900 $ ( 9,900)
Net income - - - -
Other comprehensive loss:
Unrealized holding loss
on investment securities,
net of tax - - - (34,500)
Comprehensive income - - - -
Exercise of stock options 36,000 1,800 61,100 -
Stock-based compensation - - 3,000 -
Income tax benefit of
stock options exercised - - 14,000 -
Cash dividend paid, $.07
per share - - - -
_________ ______ _________ ___________
Balance, June 30, 2008 1,201,154 60,000 1,507,000 (44,400)
Net income - - - -
Other comprehensive loss:
Unrealized holding loss
on investment securities,
net of tax - - - (35,200)
Comprehensive income - - - -
Exercise of stock options 11,225 600 2,700 -
Stock-based compensation - - 2,600 -
Income tax benefit of
stock options exercised - - 2,000 -
Cash dividend paid, $.08
per share - - - -
_________ _______ __________ ___________
Balance, June 30, 2009 1,212,379 $60,600 $1,514,300 $ (79,600)
========= ======= ========== ===========
See notes to consolidated financial statements.
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (CONTINUED)
YEARS ENDED JUNE 30, 2009 AND 2008
Retained Treasury Stock Shareholders'
______________
Earnings Shares Amount Equity
________ ______ ______ ____________
Balance, July 1, 2007 $1,931,300 19,802 $52,400 $3,356,100
__________
Net income 391,500 - - 391,500
Other comprehensive loss:
Unrealized holding loss
on investment securities, - - - ( 34,500)
net of tax ____________
Comprehensive income - - - 357,000
____________
Exercise of stock options - - - 62,900
Stock-based compensation - - - 3,000
Income tax benefit of stock
options exercised - - - 14,000
Cash dividend paid, $.07
per share (80,200) - - (80,200)
__________ _______ _______ ___________
Balance, June 30, 2008 2,242,600 19,802 52,400 3,712,800
Net income 319,500 - - 319,500
Other comprehensive loss:
Unrealized holding loss
on investment securities,
net of tax - - - ( 35,200)
____________
Comprehensive income - - - 284,300
____________
Exercise of stock options - - - 3,300
Stock-based compensation - - - 2,600
Income tax benefit of stock
options exercised - - - 2,000
Cash dividend paid, $.08
per share (94,500) - - (94,500)
__________ _______ _______ ____________
Balance, June 30, 2009 $2,467,600 19,802 $52,400 $3,910,500
========== ======= ======= ============
See notes to consolidated financial statements.
F-4
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED JUNE 30, 2009 AND 2008
2009 2008
--------- ---------
Operating activities:
Net income $ 319,500 $ 391,500
--------- ---------
Adjustments to reconcile net income to net
cash provided by (used in) operating activities:
Depreciation and amortization 205,500 213,500
Deferred income tax benefit ( 56,700) ( 43,600)
Income tax benefit of stock options
exercised 2,000 14,000
Stock-based compensation 2,600 3,000
Changes in assets and liabilities:
Trade accounts receivable (351,900) 296,000
Inventories ( 76,600) (231,800)
Prepaid and other current assets ( 6,900) ( 23,500)
Other assets 20,300 ( 300)
Accounts payable (104,400) 9,900
Customer advances ( 19,700) 231,700
Accrued expenses and taxes 18,500 6,800
--------- ---------
Total adjustments (367,300) 475,700
--------- ---------
Net cash provided by (used in)
operating ctivities ( 47,800) 867,200
--------- ---------
Investing activities:
Additional consideration for acquisition
of Altamira Instruments, Inc. (144,900) (102,800)
Purchase of investment securities,
available for sale (17,600) ( 23,800)
Redemption of investment securities,
available for sale 50,000 25,000
Capital expenditures (66,600) ( 66,400)
Purchase of intangible assets ( 9,000) ( 5,100)
--------- ---------
Net cash used in investing
activities (188,100) (173,100)
--------- ---------
Financing activities:
Proceeds from exercise of stock options 3,300 62,900
Cash dividend paid (94,500) ( 80,200)
Proceeds from line of credit 50,000 -
Repayments of line of credit (50,000) -
--------- ---------
Net cash used in financing
activities ( 91,200) ( 17,300)
--------- ---------
Net increase (decrease) in cash and
cash equivalents (327,100) 676,800
Cash and cash equivalents, beginning of year 1,065,500 388,700
----------- -----------
Cash and cash equivalents, end of year $ 738,400 $1,065,500
=========== ===========
Supplemental disclosures of cash flow information:
Cash paid for income taxes $ 125,000 $ 120,500
========== ===========
See notes to consolidated financial statements.
F-5
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
YEARS ENDED JUNE 30, 2009 AND 2008
1. Summary of Significant Accounting Policies
Nature of Operations
Scientific Industries, Inc. and its subsidiaries (the "Company")
design, manufacture, and market a variety of benchtop laboratory
equipment and catalyst research instruments. The Company is
headquartered in Bohemia, New York where it produces benchtop
laboratory equipment for research and another location in
Pittsburgh, Pennsylvania, where it produces a variety of custom-made
catalyst research instruments. The equipment sold by the Company
includes mixers, shakers, stirrers, refrigerated incubators, catalyst
characterization instruments, reactor systems and high throughput
systems.
Principles of Consolidation
The accompanying consolidated financial statements include the
accounts of Scientific Industries, Inc., Scientific Packaging
Industries, Inc., an inactive wholly-owned subsidiary, and Altamira
Instruments, Inc. ("Altamira"), a Delaware corporation and wholly-owned
subsidiary (all collectively referred to as the "Company").
All material intercompany balances and transactions have been eliminated.
Revenue Recognition
Revenue is recognized when all the following criteria are met:
o Receipt of a written purchase order agreement which is binding on
the customer.
o Goods are shipped and title passes.
o Prices are fixed.
o Collectibility is reasonably assured.
o All material obligations under the agreement have been
substantially performed.
Substantially all orders are F.O.B. shipping point, all sales are final
without right of return or payment contingencies, and there are no
special sales arrangements or agreements with any customers.
Cash and Cash Equivalents
The Company considers all highly liquid debt instruments purchased
with a maturity of three months or less to be cash equivalents. On
October 14, 2008, the FDIC announced its temporary Transaction Account
Guarantee Program, which provides full coverage for non-interest bearing
transaction deposit accounts at FDIC-insured institutions that agree to
participate in the program. The Company's bank has announced that it has
elected to participate in this program.
F-6
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
YEARS ENDED JUNE 30, 2009 AND 2008
1. Summary of Significant Accounting Policies (Continued)
Accounts Receivable
In order to record the Company's accounts receivable at their net
realizable value, the Company must assess their collectibility. A
considerable amount of judgment is required in order to make this
assessment, including an analysis of historical bad debts and other
adjustments, a review of the aging of the Company's receivables, and
the current creditworthiness of the Company's customers. The Company
has recorded allowances for receivables which it considered
uncollectible, including amounts for the resolution of potential
credit and other collection issues such as disputed invoices,
customer satisfaction claims and pricing discrepancies. However,
depending on how such potential issues are resolved, or if the
financial condition of any of the Company's customers was to
deteriorate and its ability to make required payments became
impaired, increases in these allowances may be required. The
Company actively manages its accounts receivable to minimize
credit risk. The Company does not obtain collateral for its
accounts receivable.
Customer Advances
In the ordinary course of business, customers of Altamira may prepay for
purchase orders issued to the Company. Such amounts are categorized as
liabilities under the caption customer advances.
Investment Securities
Securities available for sale are carried at fair value with
unrealized gains or losses reported in a separate component of
shareholders' equity. Realized gains or losses are determined
based on the specific identification method.
Inventories
Inventories are valued at the lower of cost (first in, first out)
or market value, and have been reduced by an allowance for excess and
obsolete inventories. The estimate is based on management's review of
inventories on hand compared to estimated future usage and sales. Cost
of work-in-process and finished goods inventories include material,
labor and manufacturing overhead.
Property and Equipment
Property and equipment are stated at cost. Depreciation of
property and equipment is provided for primarily by the straight-line
method over the estimated useful lives of the assets. Leasehold
improvements are amortized by the straight-line method over the term
of the related lease or the estimated useful lives of the assets,
whichever is shorter.
F-7
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
YEARS ENDED JUNE 30, 2009 AND 2008
1. Summary of Significant Accounting Policies (Continued)
Intangible Assets
Intangible assets consist of acquired technology, customer
relationships, non-compete agreements, patents, licenses, trademarks
and trade names. All intangible assets are amortized on a
straight-line basis over 5 years, except for customer relationships
which are amortized on an accelerated (declining-balance) basis over
their estimated useful lives. The Company continually evaluates the
remaining estimated useful lives of intangible assets that are being
amortized to determine whether events or circumstances warrant a
revision to the remaining period of amortization.
Goodwill and Intangible Assets
Goodwill represents the excess of purchase price over the fair
value of identifiable net assets of companies acquired. Goodwill and
long-lived intangible assets are tested for impairment at least annually
in accordance with the provisions of SFAS No. 142, "Goodwill and Other
Intangible Assets" ("SFAS 142"). SFAS 142 requires that goodwill be
tested for impairment at the reporting unit level (operating segment
or one level below an operating segment) on an annual basis and
between annual tests if an event occurs or circumstances change that
would more likely than not reduce the fair value of a reporting unit
below its carrying value. Application of the goodwill impairment test
requires judgment, including the identification of reporting units,
assignment of assets and liabilities to reporting units, assignment
of goodwill to reporting units, and determination of the fair value
of each reporting unit. The Company tests goodwill annually as of
June 30, the last day of our fourth fiscal quarter, of each year
unless an event occurs that would cause us to believe the value is
impaired at an interim date.
Impairment of Long-Lived Assets
The Company follows the provisions of SFAS No. 144, "Accounting for
the Impairment or Disposal of Long-Lived Assets" ("SFAS 144").
SFAS 144 requires evaluation of the need for an impairment charge
relating to long-lived assets whenever events or changes in
circumstances indicate that the carrying amount of an asset may not
be recoverable. If an evaluation for impairment is required, the
estimated future undiscounted cash flows associated with the asset
would be compared to the asset's carrying amount to determine if a
write down to a new depreciable basis is required. If required, an
impairment charge is recorded based on an estimate of future
discounted cash flows.
F-8
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
YEARS ENDED JUNE 30, 2009 AND 2008
1. Summary of Significant Accounting Policies (Continued)
Income Taxes
The Company accounts for income taxes according to the provisions
of Statement of Financial Accounting Standards (SFAS) No. 109,
"Accounting for Income Taxes." Under the liability method specified
by SFAS 109, deferred tax assets and liabilities are determined based
on the difference between the financial statement and tax basis of
assets and liabilities as measured by the enacted tax rates which will
be in effect when these differences reverse. Deferred tax expense is
the result of changes in deferred tax assets and liabilities.
Deferred income taxes result principally from the timing of the
deductibility of the rent accrual, and the use of accelerated
methods of depreciation and amortization for tax purposes.
Advertising
Advertising costs are expensed as incurred. Advertising
expense amounted to $29,400 and $21,100 for the years ended
June 30, 2009 and 2008.
Stock Compensation Plan
The Company has a ten-year stock option plan (the "2002 Plan")
which provides for the grant of options to purchase up to 100,000
shares of the Company's Common Stock, par value $.05 per share
("Common Stock"), plus to the extent that options previously granted
under the 1992 Stock Option Plan of the Company (the "Prior Plan")
expire or terminate for any reason without having been exercised,
then options exercisable for that same number of shares of Common
Stock, up to a maximum of one hundred sixty one thousand (161,000)
shares, may be granted pursuant to the 2002 Plan The 2002 Plan
provides for the granting of incentive or non-incentive stock
options as defined in the 2002 Plan and options under the 2002
Plan may be granted until 2012. Incentive stock options may be
granted to employees at an exercise price equal to 100% (or 110%
if the optionee owns directly or indirectly more than 10% of the
outstanding voting stock) of the fair market value of the shares
of Common Stock on the date of the grant. Non-incentive stock
options are to be granted at an exercise price not less than 85%
of the fair market value of the shares of Common Stock on the
date of grant. The 2002 Plan also stipulates that none of the
then members of the Board of Directors shall be eligible to
receive option grants under the 2002 Plan. The options expire
at various dates through September 2018. At June 30, 2009, 107,834
shares of Common Stock were available for grant under the 2002 Plan
and the Prior Plan.
F-9
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
YEARS ENDED JUNE 30, 2009 AND 2008
1. Summary of Significant Accounting Policies (Continued)
Stock Compensation Plan (Continued)
Stock-based compensation is accounted for using SFAS No. 123R
"Share-Based Payment" which requires compensation costs related
to stock-based payment transactions to be recognized. With limited
exceptions, the amount of compensation cost is measured based on
the grant-date fair value of the equity or liability instruments
issued. In addition, liability awards are measured each reporting
period. Compensation costs are recognized over the period that an
employee provides service in exchange for the award. During the
year ended June 30, 2009, the Company granted 1,500 options that
had a fair value of $2,500 to an employee. There were no options
granted during the year ended June 30, 2008. The fair value of the
options granted during fiscal year 2009 was determined using the
Black-Scholes-Merton option-pricing model. The weighted average
assumptions used were an expected life of 10 years; risk free
interest rate of 3.92%; volatility of 55%; and dividend yield
of 2.28%. The weighted-average value of the options granted in
2009 was $1.68 and stock-based compensation costs were $2,600 and
$3,000 for the year ended June 30, 2009 and 2008, respectively.
Stock-based compensation costs related to nonvested awards are
$1,900 to be recognized in the future.
The Company did not grant any options or warrants as compensation
for goods or services to non-employees for the years ended June
30, 2009 and 2008.
Use of Estimates
The preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America
requires management to make estimates and judgments that affect the
amounts reported in the financial statements and accompanying
notes. The accounting estimate that requires management's most
difficult and subjective judgment includes the valuation of inventory.
The actual results experienced by the Company may differ materially
from management's estimates.
Earnings Per Common Share
Basic earnings per common share is computed by dividing net income
by the weighted-average number of shares outstanding. Diluted earnings
per common share includes the dilutive effect of stock options.
F-10
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
YEARS ENDED JUNE 30, 2009 AND 2008
1. Summary of Significant Accounting Policies (Continued)
Recent Accounting Pronouncements
In June 2009, the FASB issued SFAS No. 168, "The FASB Accounting
Standards Codification and Hierarchy of Generally Accepted Accounting
Principles, a replacement of FASB Statement No. 162" ("SFAS No. 168"),
which established the FASB Accounting Standards Codification as the
source of authoritative accounting principles recognized by the FASB
to be applied in the preparation of financial statements in conformity
with generally accepted accounting principles. SFAS No. 168 explicitly
recognizes rules and interpretative releases of the SEC under federal
securities laws as authoritative GAAP for SEC registrants. SFAS No.
168 will become effective in the first fiscal quarter of fiscal year
2010 and is not expected to have a material impact on the Company's
results of operations, cash flows or financial condition.
In May 2009, the FASB issued SFAS No. 165, "Subsequent Events" ("SFAS
No. 165"). This statement provides guidance to establish general
standards of accounting for and disclosure of events that occur after
the balance sheet date but before the financial statements are issued
or are available to be issued. This statement is effective for interim
or fiscal periods ending after June 15, 2009, and is applied
prospectively. The Company adopted SFAS No. 165 in the fourth
quarter of fiscal 2009; this adoption did not have any impact on
the Company's financial condition, results of operations or cash
flows. The Company has evaluated subsequent events for recognition
or disclosure through the date these financial statements were
issued, September 24, 2009.
In April 2009, the FASB issued FASB Staff Position No. FAS 107-1 and
APB 28-1, "Interim Disclosures about Fair Value of Financial
Instruments." This Staff Position amends FASB Statement No. 107,
"Disclosures About Fair Value of Financial Instruments," to require
disclosures about fair value of financial instruments at interim
reporting periods. This Staff Position is effective for interim
reporting periods ending after June 15, 2009, with early adoption
permitted for periods ending after March 15, 2009 provided FSP
No. FAS 115-2 and FAS 124-2 are also early adopted. The Company
will adopt FSP No. FAS 107-1 in its first quarter of fiscal
2010 and does not believe it will have a material impact on its
consolidated financial statements.
In April 2009, the FASB issued FASB Staff Position ("FSP") No. FAS
141(R)-1, "Accounting for Assets Acquired and Liabilities Assumed in a
Business Combination That Arise from Contingencies"
("FSP FAS 141(R)-1"). FSP FAS 141(R)-1 amends and clarifies SFAS
No. 141 (revised 2007), "Business Combinations" ("SFAS No. 141(R)")
to address the application issues raised on initial recognition and
measurement, subsequent measurement and accounting, and disclosure
of assets and liabilities arising from contingencies in a business
combination. FSP FAS 141(R)-1 is effective on or after the
beginning of the first annual reporting on or after December
15, 2008. The Company will apply FSP FAS 141(R) -1 to any future
acquisitions that close after July 1, 2009.
F-11
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
YEARS ENDED JUNE 30, 2009 AND 2008
1. Summary of Significant Accounting Policies (Continued)
In April 2009, the FASB issued FSP Nos. FAS 115-2 and FAS 124-2,
"Recognition and Presentation of Other-Than-Temporary Impairments"
("FSP FAS 115-2 and FAS 124-2"). The objective of FSP FAS 115-2 and
FAS 124-2 is to amend the other-than-temporary impairment guidance for
debt securities to make the guidance more operational and to improve the
presentation and disclosure of other-than-temporary impairments on debt
and equity securities in the financial statements. FSP FAS 115-2 and
FAS 124-2 is effective for interim and annual reporting periods ending
after June 15, 2009, with early adoption permitted for periods ending
after March 15, 2009. The Company adopted FSP FAS 115-2 and FAS 124-2
in the fourth quarter of fiscal year 2009 and the adoption of this
standard did not have a material impact on the Company's results of
operations, cash flows or financial condition.
In April 2008, the FASB issued FSP FAS No. 142-3, "Determination of
the Useful Life of Intangible Assets" ("FSP FAS 142-3"). This
pronouncement amends SFAS No. 142, regarding the factors that should
be considered in developing the useful lives for intangible assets with
renewal or extension provisions. FSP FAS 142-3 requires an entity to
consider its own historical experience in renewing or extending similar
arrangements, regardless of whether those arrangements have explicit
renewal or extension provisions, when determining the useful life of
an intangible asset. In the absence of such experience, an entity
shall consider the assumptions that market participants would use
about renewal or extension, adjust for entity specific factors. FSP
FAS 142-3 also requires an entity to disclose information regarding
the extent to which the expected future cash flows associated with an
intangible asset are affected by the entity's intent and/or ability
to renew or extend the arrangement. FSP FAS 142-3 will be effective
for qualifying intangible assets acquired by the Company on or after
July 1, 2009. The application of FSP FAS 142-3 is not expected to
have a material impact on the Company's results of operations,
cash flows or financial position.
In December 2007, FASB issued SFAS No. 160 "Noncontrolling Interests
in Consolidated Financial Statements- and amendment to ARD No. 51"
("SFAS No. 160"). SFAS No. 160 establishes accounting and reporting
standards that require the ownership interest in subsidiaries held
by parties other than the parent be clearly identified and presented
in the consolidated balance sheets within equity, but separate from
the parent's equity; the amount of consolidated net income attributable
to the noncontrolling interest be clearly identified and presented on
the face of the consolidated statement of earnings; and changes in a
parent's ownership interest while the parent retains its controlling
financial interest in its subsidiary be accounted for consistently.
This statement is effective for fiscal years beginning on or after
December 31, 2008. SFAS No. 160 will be effective for the Company on
or after July 1, 2009. The application of SFAS No. 160 is not
expected to have a material impact on the Company's results of
operations, cash flows or financial position.
F-12
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
YEARS ENDED JUNE 30, 2009 AND 2008
1. Summary of Significant Accounting Policies (Continued)
In December 2007, the FASB issued SFAS No. 141 (revised 2007),
("SFAS 141R"), "Business Combinations," which replaces SFAS No. 141.
The statement retains the purchase method of accounting for
acquisitions, however, includes changes in the way assets and
liabilities are recognized in purchase accounting. It also changes
the recognition of assets acquired and liabilities assumed arising
from contingencies, requires the capitalization of in-process research
and development at fair value, and requires the expensing of
acquisition-related costs as incurred. SFAS 141R is effective for the
Company beginning July 1, 2009 and will apply prospectively to
business combinations completed on or after that date. The impact of
the adoption of SFAS 141R will be dependent on the extent and nature of
any further acquisitions.
In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option
for Financial Assets and Financial Liabilities- Including an amendment
of FASB Statement No. 115" (SFAS No. 159"). This statement provides a
fair value option election that allows companies to irrevocably elect
fair as the initial and subsequent measurement attribute for certain
financial assets and liabilities, which changes in fair value recognized
in earnings as they occur. SFAS No. 159 permits the fair value option
election on an instrument by instrument basis at initial recognition of
an asset or liability or upon an event that gives rise to a new basis
of accounting for that instrument. SFAS No. 159 is effective as of the
beginning of an entity's first fiscal year that begins after November
15, 2007. SFAS No. 159 became effective for the Company beginning on
July 1, 2008. The Company has not applied the elective provisions of
SFAS No. 159.
In September 2006, the FASB issued SFAS 157, "Fair Value Measurements"
("SFAS 157"). SFAS 157 defines fair value, establishes a framework for
measuring fair value in generally accepted accounting principles (GAAP),
and expands disclosures about fair value measurements. SFAS 157 will be
applied prospectively and will be effective for periods beginning after
November 15, 2007. In February 2008, the FASB issued FASB Staff
Position No. FAS 157-1, "Application of FASB Statement No. 157 to
FASB Statement No. 13 and Other Accounting Pronouncements That Address
Fair Value Measurement for Purposes of Lease Classification or
Measurement under Statement 13 and FASB Staff Position No. FAS
157-2, Effective Date of FASB Statement No. 157." Collectively,
the Staff Positions defer the effective date of SFAS 157 to fiscal
years beginning after November 15, 2008, for non financial assets
and non financial liabilities except for items recognized or
disclosed at fair value on a recurring basis at least annually,
and amend the scope of SFAS 157. The Company is currently
evaluating the effect, if any, of SFAS 157 on the Company's
consolidated financial statements.
F-13
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
YEARS ENDED JUNE 30, 2009 AND 2008
2. Acquisition
On November 30, 2006, the Company acquired all of the outstanding
capital stock of Altamira. The acquisition was pursuant to a Stock
Purchase Agreement (the "Agreement") whereby the Company paid or
issued to the sellers $400,000 in cash and 125,000 shares of
the Company's Common Stock and agreed to make additional cash payments
equal to 5%, subject to adjustment, of the net sales of Altamira for
each of five periods - December 1, 2006 to June 30, 2007, each of the
fiscal years ending June 30, 2008, 2009, and 2010, and July 1, 2010
to November 30, 2010.
Altamira's principal customers are universities, government
laboratories, and chemical and petrochemical companies. The
instruments, which are customizable to the customers' specifications,
are sold on a direct basis.
In conjunction with the acquisition of Altamira, management of the
Company valued the tangible and intangible assets acquired, including
goodwill, customer relationships, non-compete agreements, and certain
technology, trade names and trademarks. The carrying amounts of
goodwill and other intangible assets are presented in Note 7, "Goodwill
and Other Intangible Assets" which represent the valuations determined
in conjunction with the acquisition. In addition, other fair market
value adjustments were made in conjunction with the acquisition,
primarily adjustments to property and equipment, and inventory.
As of June 30, 2009 and 2008, the adjusted aggregate purchase
price was allocated to assets acquired and liabilities assumed as
follows:
2009 2008
___________ ___________
Current assets $ 734,000 $ 734,000
Property and equipment 140,300 140,300
Non-current assets 25,100 25,100
Goodwill 265,400 158,400
Other intangible assets 639,000* 639,000*
Current liabilities (561,900) (561,900)
------------ ------------
Net purchase price $ 1,241,900 $ 1,134,900
============ ============
*Of the $639,000 of other intangible assets, $237,000 was allocated
to customer relationships with an estimated useful life of 10 years,
$300,000 was allocated to technology including trade names and
trademarks with a useful life of 5 years, and $102,000 was allocated
to a non-compete agreement with an estimated useful life of 5 years.
The amount allocated to the customer relationships is being amortized
on an accelerated (declining balance) method and the other intangibles
are being amortized on a straight-line basis.
F-14
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
YEARS ENDED JUNE 30, 2009 AND 2008
3. Segment Information and Concentrations
The Company views its operations as two segments: the manufacture
and marketing of standard benchtop laboratory equipment for research
in university, hospital and industrial laboratories sold primarily
through laboratory equipment distributors ("Benchtop Laboratory
Equipment Operations"), and the manufacture and marketing of custom-made
catalyst research instruments for universities, government laboratories,
and chemical and petrochemical companies sold on a direct basis
("Catalyst Research Instruments Operations").
Segment information is reported as follows:
Benchtop Catalyst Corporate
Laboratory Research and
Equipment Instruments Other Consolidated
__________ ___________ _________ ____________
June 30, 2009:
Net Sales $3,848,400 $2,140,700 $ - $5,989,100
Foreign Sales 2,229,000 463,900 - 2,692,900
Segment Profit 429,900 ( 33,700) - 396,200
Segment Assets 2,199,700 1,632,800 998,500 4,831,000
Long-Lived Assets
Expenditures 41,100 25,500 - 66,600
Depreciation and
Amortization 58,700 146,800 - 205,500
Benchtop Catalyst Corporate
Laboratory Research and
Equipment Instruments Other Consolidated
__________ ___________ _________ ____________
June 30, 2008:
Net Sales $3,770,500 $2,898,900 $ - $6,669,400
Foreign Sales 1,925,900 1,484,300 - 3,410,200
Segment Profit 350,600 193,900 - 544,500
Segment Assets 2,845,100 1,029,300 902,400 4,776,800
Long-Lived Assets
Expenditures 57,000 9,400 - 66,400
Depreciation and
Amortization 54,700 158,800 - 213,500
F-15
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
YEARS ENDED JUNE 30, 2009 AND 2008
3. Segment Information and Concentrations (Continued)
Certain information relating to the Company's export sales and
principal customers follows:
2009 2008
___________ ___________
Export sales (principally Europe and Asia) $ 2,692,900 $ 3,410,200
Customers in excess of 10% of net sales:
Largest in 2008 (a) - 755,800
(a) Accounts receivable from the customer amounted to approximately
8% of total accounts receivable at June 30, 2008.
The Company purchased approximately 11% and 24% of inventory from one
supplier for the years ended June 30, 2009 and 2008.
4. Fair Value of Financial Instruments
SFAS No. 157, "Fair Value Measurements" defines the fair value of
financial instruments as the amount that would be received to sell
an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date. Fair value
measurements do not include transaction costs.
SFAS No. 157 expands the disclosure requirements around fair value
and establishes a fair value hierarchy for valuation inputs. The
hierarchy prioritizes the inputs into three levels based on the
extent to which inputs used in measuring fair value are observable
in the market. Each fair value measurement is reported in one of
the three levels, which is determined by the lowest level input
that is significant to the fair value measurement in its entirety.
These levels are described below:
Level 1 Inputs that are based upon unadjusted quoted prices
for identical instruments traded in active markets.
Level 2 Quoted prices in markets that are not considered to
be active or financial instruments for which all significant inputs
are observable, either directly or indirectly.
Level 3 Prices or valuation that require inputs that are
both significant to the fair value measurement and unobservable.
The following tables set forth by level within the fair value
hierarchy the Company's financial assets that were accounted for at
fair value on a recurring basis at June 30, 2009 according to the
valuation techniques the Company used to determine their fair values:
Fair Value Measurements Using Inputs
Considered as
Fair Value at
June 30, 2009 Level 1 Level 2 Level 3
_____________ __________ _______ ________
Cash and cash equivalents $ 738,400 $ 738,400 $ - $ -
Available for sale securities 605,500 605,500 - -
---------- ---------- ------- --------
Total $1,343,900 $1,343,900 $ - $ -
========== ========== ======= ========
F-16
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
YEARS ENDED JUNE 30, 2009 AND 2008
4. Fair Value of Financial Instruments
Investments in marketable securities classified as available-for-sale
by security type at June 30, 2009 and 2008 consisted of the following:
Unrealized
Fair Holding Gain
Cost Value (Loss)
_____________ ________ ____________
At June 30, 2009:
Available for sale:
Equity securities $ 6,200 $ 8,900 $ 2,700
Mutual funds 678,900 596,600 (82,300)
__________ _________ __________
$ 685,100 $ 605,500 $ (79,600)
========== ========= ==========
Unrealized
Fair Holding Gain
Cost Value (Loss)
_____________ ________ ____________
At June 30, 2008:
Available for sale:
Equity securities $ 7,800 $ 10,200 $ 2,400
Mutual funds 669,000 622,200 (46,800)
Callable bonds 50,000 50,000 -
__________ _________ __________
$ 726,800 $ 682,400 $ (44,400)
========== ========= ==========
5. Inventories
2009 2008
__________ __________
Raw Materials $1,068,500 $1,037,900
Work-in-process 321,000 288,600
Finished goods 208,500 194,900
__________ __________
$1,598,000 $1,521,400
========== ==========
F-17
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
YEARS ENDED JUNE 30, 2009 AND 2008
6. Property and Equipment
Useful Lives
(Years) 2009 2008
____________ __________ __________
Automobiles 5 $ 21,000 $ -
Computer equipment 3-5 119,100 134,100
Machinery and equipment 3-7 483,400 472,600
Furniture and fixtures 4-10 162,900 163,500
Leasehold improvements 3-5 64,100 64,100
_________ _________
850,500 834,300
Less accumulated depreciation
and amortization 609,300 586,900
_________ _________
$ 241,200 $ 247,400
========= =========
Depreciation expense was $72,900 and $66,100 for the years ended
June 30, 2009 and 2008, respectively.
7. Goodwill and Other Intangible Assets
In conjunction with the acquisition of Altamira, management of the
Company valued the tangible and intangible assets acquired, including
customer relationships, non-compete agreements and technology which
encompasses trade names, trademarks and licenses. The valuation
resulted in an initial negative goodwill of approximately $91,500 on
the date of acquisition which was subsequently adjusted to positive
goodwill of $265,400 and $158,400 at June 30, 2009 and 2008, all of
which is deductible for tax purposes. The related agreement provides
for contingent payments to the former shareholders based on net sales
of the Catalyst Research Instrument Operations subject to certain
limits, which are expected to be earned and paid. Additional
consideration amounted to approximately $107,000 and $145,000 for
the years ended June 30, 2009 and 2008, respectively.
The components of intangible assets are as follows:
Useful Accumulated
Lives Cost Amortization Net
______ ________ ____________ ____________
At June 30, 2009:
Technology 5 yrs. $300,000 $ 155,000 $ 145,000
Customer relationships 10 yrs. 237,000 129,200 107,800
Non-compete agreement 5 yrs. 102,000 52,700 49,300
Other intangible assets 5 yrs. 124,400 95,600 28,800
________ _________ _________
$763,400 $ 432,500 $ 330,900
======== ========= =========
F-18
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
YEARS ENDED JUNE 30, 2009 AND 2008
7. Goodwill and Other Intangible Assets (Continued)
Useful Accumulated
Lives Cost Amortization Net
______ ________ ____________ ____________
At June 30, 2008:
Technology 5 yrs. $300,000 $ 95,000 $ 205,000
Customer relationships 10 yrs. 237,000 90,600 146,400
Non-compete agreement 5 yrs. 102,000 32,300 69,700
Other intangible assets 5 yrs. 115,500 82,000 33,500
________ _________ _________
$754,500 $ 299,900 $ 454,600
======== ========= =========
Total amortization expense was $132,600 and $147,400 in 2009 and 2008.
Estimated future intangible assets amortization expense is as follows:
Fiscal Years
_____________
2010 $ 121,400
2011 109,500
2012 52,600
2013 13,000
2014 9,300
Thereafter 25,100
-----------
$ 330,900
===========
8. Bank Line of Credit
The Company has a line of credit with Capital One Bank, N.A. (the
"Bank"), which provides for maximum borrowings of up to $500,000.
Interest is charged at the Bank's prime rate. The Company borrowed
and repaid $50,000 under this line of credit during the year ended
June 30, 2009. The Company did not utilize a previous line of credit
during the fiscal year ended June 30, 2008. The line of credit is
collateralized by the Company's assets to the extent borrowed and
outstanding and any outstanding amounts are due and payable on
November 1, 2009.
F-19
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
YEARS ENDED JUNE 30, 2009 AND 2008
9. Employee Benefit Plans
The Company has 401(k) profit sharing plans covering its employees,
which provide for voluntary employee salary contributions not to
exceed the statutory limitations provided by the Internal Revenue
Code. One plan provides for company matching of 50% of each
Benchtop Laboratory Equipment Operations participant's salary
deferral election, up to a maximum amount for each participant of
2% of their compensation, while the second plan provides for
matching the Altamira employee contributions up to 4% of their
compensation. Total employer matching contributions amounted to
$29,300 and $26,800 for the years ended June 30, 2009 and 2008,
respectively.
10. Commitments and Contingencies
The Company is obligated through January 2015 under a
noncancelable operating lease, which was renewed during 2008,
for its Bohemia, New York premises, which requires minimum annual
rental payments plus other expenses, including real estate taxes
and insurance. In accordance with generally accepted accounting
principles, the future minimum annual rental expense, computed on
a straight-line basis, is approximately $209,400 under the terms
of the lease. Rental expense for the Bohemia facility amounted to
approximately $225,300 in 2009 and $208,600 in 2008. Accrued rent,
payable in future years, amounted to $58,400 and $42,900 at
June 30, 2009 and 2008. Commencing August 2008, the Company
has a sublease agreement through August 2012 for a portion of
its warehouse space at an annual sublease income of approximately
$16,200.
The Company is also obligated under an operating lease for its
facility in Pittsburgh, Pennsylvania. The lease, which commenced
on August 1, 2006, has a term of five years through July 31, 2011,
subject to early termination upon 180 day notice. The lease requires
monthly minimum rental payments of $4,500 for the first two years and
$4,700 monthly thereafter, with a Company option to renew for an
additional five years. Total rental expense for the Pittsburgh
facility was $54,000 in each of 2009 and 2008. There are no other
significant expenses related to this lease.
The Company's approximate future minimum rental payments under all
leases are as follows:
Bohemia
Facility(net
of sublease Pittsburgh
Fiscal Years income) Facility Total
____________ _____________ __________ _____________
2010 $ 187,900 $ 56,400 $ 244,300
2011 191,900 56,400 248,300
2012 199,600 4,700 204,300
2013 222,900 - 222,900
2014 234,800 - 234,800
Thereafter 140,100 - 140,100
------------ ---------- ------------
$ 1,177,200 $ 117,500 $ 1,294,700
============ ========== ============
F-20
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
YEARS ENDED JUNE 30, 2009 AND 2008
10. Commitments and Contingencies (Continued)
The Company has employment contracts with its President and Executive
Vice President for the twenty-four month period ending December 31,
2010, providing for annual base salaries of $130,000 and $120,000,
respectively, for the first twelve month period. Each contract
provides for a performance bonus for the first twelve month period
of $5,000. The base salary for each contract for the second twelve
month period of the term is to be determined by the Company's Board
of Directors, but not less than the base salary for the first twelve
month period. The bonus, if any, for the second twelve month period
is also to be determined by the Board of Directors. There were no
bonuses paid during the fiscal year ended June 30, 2009 and a bonus
of $10,000 was paid to each officer during the fiscal year ended
June 30, 2008.
The Company has an employment contract with the President of Altamira
for the two years ending November 30, 2010 which may be extended by
mutual consent for an additional year but not beyond November 30,
2012. The contract provides for an annual base salary of $115,000
during the first twelve month period, and $121,900 for the second
twelve month period, plus discretionary bonuses for each of the two
years. The Company has the option to pay, with the employee's
consent, the increase in base salary for the second twelve month
period in cash or stock options.
The Company has a consulting agreement which expires on December 31,
2010 with an affiliate of a member of its Board of Directors for
marketing consulting services. The agreement provides that the
consultant be paid a monthly fee of $3,000 for a certain number of
consulting days as defined in the agreement. Consulting expense
related to this agreement amounted to $36,000 for each of the years
ended June 30, 2009 and 2008.
During the fiscal year ended June 30, 2009, the Company entered into a
two year consulting agreement for the two year period ending March 31,
2011 with a member of its Board of Directors for administrative
services. The agreement provides that the consultant will be paid at
the rate of $85 per hour. Consulting expense related to this
agreement amounted to $10,400 for the fiscal year ended June 30, 2009.
F-21
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
YEARS ENDED JUNE 30, 2009 AND 2008
11. Income Taxes
Income taxes for 2009 and 2008 were different from the amounts computed
by applying the Federal income tax rate to the income before income
taxes due to the following:
2009 2008
__________________ _________________
% of % of
Pre-tax Pre-tax
Amount Income Amount Income
_________ _______ _________ _______
Computed "expected" income tax $141,400 35.0% $190,600 35.0%
Research and development
credits ( 21,200) (5.2) (15,000) (2.8)
State income taxes, net of
Federal effect - - 12,500 2.3
Other, net (35,800) (8.9) (35,100) (6.4)
_________ _______ __________ ______
Actual income taxes $ 84,400 20.9% $153,000 28.1%
========= ======= ========== ======
Deferred tax assets and liabilities consist of the following:
2009 2008
__________ __________
Deferred tax assets:
Amortization of intangibles $ 99,000 $ 73,000
Rent accrual 22,200 16,300
Other 63,400 31,300
_________ _________
184,600 120,600
Deferred tax liability:
Depreciation of property
and amortization of goodwill (57,000) (59,000)
__________ __________
Net deferred tax assets $ 127,600 $ 61,600
========== ==========
The breakdown between current and long-term deferred tax assets and
liabilities is as follows:
2009 2008
__________ __________
Current deferred tax assets $ 63,400 $ 31,400
_________ _________
Long-term deferred tax assets 121,200 89,200
Long-term deferred tax liabilities (57,000) (59,000)
__________ __________
Net long-term deferred tax asset 64,200 30,200
__________ __________
Net deferred tax assets $ 127,600 $ 61,600
========== ==========
F-22
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
YEARS ENDED JUNE 30, 2009 AND 2008
11. Income Taxes (Continued)
Effective July 1, 2007, the Company adopted the provisions of FASB
Interpretation No. 48 ("FIN 48"). FIN 48 clarifies the accounting for
uncertainty in income taxes recognized in an enterprise's financial
statements in accordance with FASB 109. This Interpretation
prescribes a recognition threshold and measurement attribute for the
financial statement recognition and measurement of a tax position
taken or expected to be taken in a tax return. FIN 48 also provides
guidance on derecognition, classification, interest and penalties,
accounting in interim periods, disclosure, and transition. FIN 48 is
effective for fiscal years beginning after December 15, 2006. The
cumulative effect, if any, of applying FIN 48 is to be reported as an
adjustment to the opening balance of retained earnings in the year of
adoption. The impact of the Company's reassessment of its tax
positions in accordance with FIN 48 did not have an effect on the
results of operations, financial condition or liquidity. As of June
30, 2009, the Company does not have any unrecognized tax benefits
related to various federal and state income tax matters.
The Company's policy is to recognize interest and penalties on any
unrecognized tax benefits as a component of income tax expense. As
of the date of adoption of FIN 48, the Company did not have any
accrued interest or penalties associated with any unrecognized tax
benefits. The Company is subject to U.S. federal income tax, as well
as various state jurisdictions. The Company is currently open to audit
under the statute of limitations by the federal and state jurisdictions
for the years ending June 30, 2006 through 2008. The Company does not
anticipate any material amount of unrecognized tax benefits within the
next 12 months.
12. Stock Options
Option activity is summarized as follows:
Fiscal 2009 Fiscal 2008
_________________ __________________
Weighted- Weighted-
Average Average
Exercise Exercise
Shares Price Shares Price
_______ _______ _______ ________
Shares under option:
Outstanding, beginning of year 64,001 $ 1.60 104,001 $ 1.62
Granted 1,500 3.27 - -
Exercised (17,000) .84 (36,000) 1.75
Forfeited ( 4,000) 1.88 ( 4,000) .84
________ ________
Outstanding, end of year 44,501 1.90 64,001 1.60
________ _______ ________ ________
Options exercisable at year-end 43,000 $ 1.88 62,501 $ 1.57
________ _______ ________ ________
Weighted average fair value per
share of options granted
during fiscal 2009 and 2008 $ 3.27 not
======= applicable
F-23
SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
YEARS ENDED JUNE 30, 2009 AND 2008
12. Stock Options (Continued)
As of June 30, 2009 As of June 30, 2009
Options Outstanding Exercisable
_______________________________________________ ______________________
Weighted-
Average Weighted- Weighted-
Range Remaining Average Average
Exercise Number Contractual Exercise Number Exercise
Prices Outstanding Life (Years) Price Outstanding Price
_________ ___________ ____________ _________ ___________ _________
$2.40-$3.27 22,500 4.04 $ 2.61 21,000 $ 2.57
$.83-$1.33 22,001 2.40 1.22 22,000 1.22
________ ________
44,501 43,000
________ ________
As of June 30, 2008 As of June 30, 2008
Options Outstanding Exercisable
_______________________________________________ ______________________
Weighted-
Average Weighted- Weighted-
Range Remaining Average Average
Exercise Number Contractual Exercise Number Exercise
Prices Outstanding Life (Years) Price Outstanding Price
_________ ___________ ____________ _________ ___________ _________
$1.88-$3.10 25,000 4.00 $ 2.46 23,500 $ 2.41
$.83-$1.33 39,001 2.37 1.06 39,001 1.06
________ ________
64,001 62,501
________ ________
13. Earnings Per Common Share
Earnings per common share data was computed as follows:
2009 2008
__________ __________
Net income $ 319,500 $ 391,500
__________ __________
Weighted average common shares
outstanding 1,184,884 1,159,494
Effect of dilutive securities 25,026 46,742
__________ __________
Weighted average dilutive common
shares outstanding 1,209,910 1,206,236
__________ __________
Basic earnings per common share $ .27 $ .34
========== ==========
Diluted earnings per common share $ .26 $ .32
========== ==========
Approximately 6,500 shares of the Company's common stock issuable
upon the exercise of outstanding options were excluded from the
calculation of diluted earnings per common share for the year
ended June 30, 2009, because the effect would be anti-dilutive as
the exercise price for such shares was greater than the average
fair market value during the year.